Exosomes as a new frontier of cancer liquid biopsy

Dan Yu1, Yixin Li1, Maoye Wang1, Jianmei Gu2, Wenrong Xu1, Hui Cai3, Xinjian Fang4* and Xu Zhang1,3,4*

Abstract

Liquid biopsy, characterized by minimally invasive detection through biofluids such as blood, saliva, and urine, has emerged as a revolutionary strategy for cancer diagnosis and prognosis prediction. Exosomes are a subset of extracellular vesicles (EVs) that shuttle molecular cargoes from donor cells to recipient cells and play a crucial role in mediating intercellular communication. Increasing studies suggest that exosomes have a great promise to serve as novel biomarkers in liquid biopsy, since large quantities of exosomes are enriched in body fluids and are involved in numerous physiological and pathological processes. However, the further clinical application of exosomes has been greatly restrained by the lack of high-quality separation and component analysis methods. This review aims to provide a comprehensive overview on the conventional and novel technologies for exosome isolation, characterization and content detection. Additionally, the roles of exosomes serving as potential biomarkers in liquid biopsy for the diagnosis, treatment monitoring, and prognosis prediction of cancer are summarized. Finally, the prospects and challenges of applying exosome-based liquid biopsy to precision medicine are evaluated.

Keywords: Exosome, Cancer, Liquid biopsy, Biomarker, Precision medicine

Introduction

Cancer is a leading cause of death around the world [1]. Mounting evidence suggests that the development of cancer is a dynamic process and diverse components are involved, including tumor cells, stromal cells, and immune cells. Up to now, tissue biopsy has been considered as the most common method for cancer diagnosis [2]. However, the extracted small tissues fail to represent tumor heterogeneity or monitor dynamic tumor progression, and the potential of metastasis may be increased by this invasive method, finally leading to poor survival and prognosis [3]. Due to minimal invasion, liquid biopsy, which collects the specimen of biofluids such as blood and urine, has drawn widespread attention and generated more opportunities for cancer diagnosis as well as real-time monitoring [4]. Exosomes, with a diameter of 40-160 nm, are lipid bi-layer membrane vesicles that are actively released by most cells and stably circulate in body fluids [5, 6]. Originally underestimated as vehicles for disposal of cellular waste products, exosomes are now being recognized as important players in intercellular communication [4, 7]. Accumulating evidence suggests that a variety of bioactive molecules, including nucleic acids, proteins, and lipids, are enriched in exosomes and could be transferred from donor cells to recipient cells, leading to the intracellular transfer of information [4, 8–10]. The bioactive cargoes in exosomes may be uptaken by recipient cells, facilitating tumorigenesis and tumor progression. In addition, exosomes are involved in the formation of pre-metastatic niche, tumor angiogenesis, and tumor immune suppression. Moreover, exosomes could reflect the altered physiological and pathological state of their parental cells [11–14]. These findings have led to the idea that analyzing the circulating exosomes and their derived cargoes may provide new opportunities for cancer liquid...
biopsy (Fig. 1), highlighting the potential of exosomes as biomarkers for cancer diagnosis, progression monitoring, and prognosis prediction.

Currently, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes have become the three main branches of liquid biopsy [15, 16]. Compared with CTCs and ctDNA, exosomes have shown greater advantages in liquid biopsy. First, the presence of large amounts of exosomes (~ $10^9$ particles/mL) in biofluids contributes to relatively easy obtaining of vesicles, while only several CTCs exist in 1 mL blood samples [14]. Second, exosomes are secreted by living cells and inherent abundant biological information from their parental cells. Therefore, exosome is more representative than ctDNA, which limitedly reflects the information of apoptotic or dead tumor cells [11, 14]. Third, exosomes are innately stable because of their lipid bilayers, and thus stably circulate in physiological conditions even in harsh tumor microenvironment. The high biological stability allows long-term storage of specimens for exosome isolation and detection [17]. Notably, one of the big challenges for the application of exosomes in liquid biopsy is isolation with high efficiency and purity, which arises from their nanoscale size and intrinsic heterogeneity [18–20]. Moreover, since cancerous exosomes represent only a small fraction of all exosomes present in body fluids, ultrasensitive and specific detection is a prerequisite for the development of exosome-based cancer diagnostics. To date, a variety of methods have been developed for exosome isolation as well as the detection of exosomal proteins and nucleic acids [21–26]. Although notable progress has been made, the limited sensitivity and specificity, low purity and throughput remain significant challenges for academic research and practical use [27].

*Fig. 1* Exosomes as a new target for liquid biopsy. Exosomes are enriched in body fluids and are critically involved in tumorigenesis, tumor progression and metastasis. Compared with CTC and ctDNA, exosomes show superior characteristics such as living-cell secreted vesicles, large amounts and stable circulation. Traditional and advanced technologies have been used to separate exosomes from various body fluids and to detect exosomal cargoes. The detection of specific molecules of exosome may provide a new strategy for cancer diagnosis, progression monitoring, and prognosis prediction.
Therefore, active research is needed to develop an easy-to-operate, high-sensitivity and high-purity platform for exosome separation and detection. In this review, we discussed about recent advance in the isolation and detection of exosomes as well as their clinical application with an emphasis on the newly developed techniques for exosome separation and detection. Furthermore, the application of exosomes as potential biomarkers in cancer liquid biopsy was summarized.

**Exosome biogenesis and contents**

Exosomes are a heterogeneous group of membrane-structured vesicles actively released by most cells and could be found in many human body fluids, such as blood, saliva, tear and urine [4]. The process of exosome biogenesis involves invagination of plasma membrane, formation of multivesicular bodies (MVBs) and exosome secretion [28]. MVBs are endocytic structures formed by the inward budding of endosomal membranes. Vesicles accumulating inside of MVBs, named intraluminal vesicles (ILVs), are released as exosomes by the fusion of MVBs with plasma membrane [4] (Fig. 2). Extensive studies suggest that donor cell-derived bioactive molecules are enriched in exosomes, which indicates the crucial role of exosomes in genetic information exchange [4, 28]. Notably, the specific RNA components in exosomes have shown great differences compared to those in their parental cells, which may be attributed to the unique process of cargo sorting during exosome formation [29]. The mechanisms of cargo sorting are still unclear, both endosomal sorting complex required for transport (ESCRT)-dependent manner [30, 31] and ESCRT-independent mechanism have been reported to participate in this process [32, 33]. Intriguingly, proteins such as tetraspanins (CD9, CD63 and CD81), heat shock proteins (HSP60, HSP70) and ESCRT-associated components (Alix and TSG101) have been confirmed to be present in exosomes, which provides certain markers for their identification and detection [34].

Increasing studies have shown that various disease-related proteins and nucleic acids are loaded into exosomes and differentially expressed in tumors of different origin. Hoshino et al. indicated that plasma-derived exosomes could identify specific cancer types and distinguish tumor sources by proteomic analysis. They found that 51 and 19 plasma-derived exosome proteins were specifically identified in pancreatic and lung cancer, respectively [35]. In addition, exosomal CD63 was reported to be high in ovarian cancer while low in lung cancer [36]. CD317 and epidermal growth factor receptors (EGFR) were highly expressed on non-small cell lung cancer (NSCLC)-derived exosomes [37]. Compared with

![Fig. 2 The biogenesis, contents, and internalization of exosomes. Exosomes are vesicles derived from the fusion of multivesicular bodies with plasma membranes. Cytoplasmic contents of donor cells such as nucleic acids and proteins are sorted into exosomes and are delivered to recipient cells through the manner of endocytosis, phagocytosis, direct fusion or direct binding (receptor-ligand interaction).](image-url)
healthy subjects, glypican-1 (GPC-1) was found to significantly increase in serum exosome of patients with pancreatic cancer and could be used for the early detection of pancreatic cancer with 100% diagnostic specificity and sensitivity [38]. In addition to proteins, nucleic acids such as miRNA, mRNA, and IncRNA are differentially distributed in exosomes and could be used as specific cancer biomarkers. For instance, mutant EGFRvIII mRNA was detected in serum exosomes of glioblastoma patients [39]. Zhou et al. reported that the expression level of exosomal miR-15a-5p was 7-19 times higher in endometrial cancer than that in other cancer types [40]. Additionally, high expression of exosomal miR-1247-3p was positively associated with lung metastasis from liver cancer, which indicated a poor outcome [41]. Given that exosomes are secreted by living cells, the specific contents in exosomes could reflect the pathophysiological state of their parental cells, which makes them useful biomarkers for dynamic monitoring of disease progression [42]. In general, cargoes sorted into exosomes can not only supply additional characteristics for their identification, but also provide promising biomarkers for diagnosis, treatment monitoring, and prognosis prediction in patients with cancer, which offers a new tool for liquid biopsy.

**Methods for exosome isolation and enrichment**

Due to unique formation manner and specific cargo sorting process, exosomes are heterogeneous in size and molecular contents. Exosome separation and enrichment from complicated biological components is essential for basic study and clinical translation. Up to now, a number of methods have been developed that are significantly varied in the amount and purity of isolated exosomes.

**Conventional isolation methods**

- **Ultracentrifugation-based separation**

As the gold standard for exosome separation, ultracentrifugation is the most commonly used method [43], including differential ultracentrifugation and gradient density ultracentrifugation. Conventional differential ultracentrifugation was first proposed by Johnstone et al. to isolate exosomes from culture medium of reticulocytes [44]. Typically, low-speed centrifugation (300 g) is first employed to remove cellular debris, while 20,000 g speed of centrifugation is utilized to eliminate other large vesicles. A high force (100,000 g) is finally utilized to sediment exosomes. However, this method needs costly instrument and has contamination with aggregated proteins. More centrifugation cycles may obtain a purer outcome but lead to lower recovery. Gradient density ultracentrifugation is a better alternative to obtain exosomes with higher purity [45]. During centrifugation, different sizes of particles from two or more solutions are separated into different layers, whose density increases from top to bottom. Based on this, the method has been applied to separate exosomes, which have been found to float with densities of 1.15 to 1.19 g/mL [45, 46]. Although with higher purity than ultracentrifugation, limitations such as time-consuming process and the requirement of large biofluid volume have largely restrained its use in clinical application.

**Size-based separation**

The feature of fixed-range diameters allows for the possibility to separate exosomes by size-based methods. Filtration is one of the size-based approaches for exosome separation by using membrane filters with specific pore sizes, which has the advantages of simple operation and effective purification but disadvantage of low yield [47]. Ultrafiltration is usually applied to concentrate exosomes from large amounts of original materials such as cell culture medium [48]. Currently, the combination of ultrafiltration with ultracentrifugation has been widely employed, in which filtration is used to remove cells and large vesicles while the purification of exosomes is achieved by ultracentrifugation [49]. Moreover, size-exclusion chromatography (SEC) could separate biomolecular components according to the size of sample and pore size of gel. During the separation, large molecules are eluted early, while small molecules or particles directly diffuse into the pores [50]. Anita N Böing et al. developed an SEC-based protocol by cross-linked sepharose CL-2B column, which could efficiently isolate exosomes with a diameter larger than 70 nm from platelet-free supernatant [50]. Guo et al. showed that CL-6B column had better performance than CL-2B column in particle yields and purity of exosomes [51]. Compared with centrifugation and filtration methods, SEC has the advantages of gentle processing and nondestructive outcomes [52]. Moreover, the combination of SEC with ultracentrifugation may have an improved recovery and purity [53].

**Precipitation techniques**

As for precipitation techniques, highly hydrophilic polymer is used to competitively bind to water molecules around the exosomal membrane, thereby reducing the solubility and finally achieving low input volume of exosome separation. To date, polyethylene glycol (PEG) is the most commonly used polymer for exosome separation [54]. An exosome purification method called ExtraPEG was proposed by Rider et al., which could rapidly enrich exosomes and obtain sufficient contents harvested from vesicles for downstream analysis [55]. Recently, many commercial kits that rely on precipitation techniques have been developed for exosome isolation.
and enrichment, such as ExoQuick™ and Total Exosome Isolation. Study from Ding et al. indicated that ExoQuick™ could generate a relatively high yield of exosomes compared with other kits [56]. However, this method has been often criticized for the high cost and contamination of coprecipitated protein aggregates.

**New enrichment methods**

The discoveries of exosome-specific markers and components provide a new avenue for separating exosomes as well as exosome subsets (Fig. 3). Through antibodies and aptamers that specifically target tumor-associated proteins such as GPC-1 and EpCAM (epithelial cell adhesion molecule), exosomes of cancer cell origin could be well distinguished from that of normal cell [57]. Moreover, the applications of microbeads, microfluid chip and thermophoresis enabled the rapid and convenient enrichment of exosomes. Herein, we summarized the advantages and limitations of new approaches for exosome enrichment (Table 1).

**Immunoaffinity enrichment**

Owing to the priority of simplicity and specificity, immunoaffinity isolation strategy has been used for exosome enrichment in many studies (Fig. 3A). For example, anti-CD81 functionalized microfluidic chip was fabricated by Zhang et al. to isolate exosomes from plasma samples [70]. Yang et al. reported an integrated microfluidic device for exosome separation through forming a sandwich structure of AuNC-exosome-AuR complexes [58] (Fig. 3Aa). This device achieved a yield of $5 \times 10^9$ particles from 5 mL urine sample in 30 min. Nevertheless, the dissociation of captured exosomes remains a big challenge, which arises from the strong affinity between antigen and antibody. To address this challenge, Kang et al. developed an exosome-specific dual-patterned immunofiltration

---

Fig. 3  New technologies for the isolation of exosomes. A Immunoaffinity/ immunomagnetic enrichment. Copyright 2020 by Yang [58], 2017 by Kang [59], 2018 by Cai [60], 2020 by Sun [61]. B Physical feature-based separation. Copyright 2017 by Liu [62], 2019 by Sunkara V [63], 2019 by Hattori [64]. C Lipid mediated-separation. Copyright 2018 by Xu [65], 2021 by Jiang [66]. D Acoustic-based isolation / Thermophoretic enrichment. Copyright 2021 by Tayebi [67], 2019 by Liu [68], 2021 by Tian [69].
Table 1 The techniques for exosome separation

| Techniques                     | Methods                          | Advantages                                      | Disadvantages                                                                 | Prominent examples                                             | Ref.     |
|-------------------------------|----------------------------------|-------------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------------------------|----------|
| Conventional techniques       |                                  |                                                 |                                                                                |                                                                  |----------|
| Ultracentrifugation-based     | Differential ultracentrifugation | High purity; established protocol;             | Lengthy process; large sample volume; requires ultracentrifuge               | Separation of EVs from reticulocyte culture medium              | [44]     |
| Separation                    | Gradient density ultracentrifuga- | High purity;                                  | Lengthy process; large sample volume; requires ultracentrifuge               | Sucrose gradient-purified prostasomes                          | [46]     |
| Size-based Separation         | Ultracentrifugation with ultrafil- | High purity; high yield                        | Contamination of same-sized vesicles; lack specificity; difficulty in scaling | Separation of urinary exosomes                                 | [49]     |
|                              | traition                        |                                                  |                                                                                |                                                                  |          |
|                              | size-exclusion chromatography    | High yield; gentle processing                   | Contamination of same-sized vesicles; lack specificity; difficulty in scaling | Isolation of EVs from platelet-free supernatant of platelet concen- | [50]     |
| Precipitation                 | Polyethylene glycol precipitation| Simple; fast isolation                         | Lack specificity; much contamination; difficulty in scaling                  | Isolation of exosomes from plasma, cell culture supernatant    | [49, 54] |
|                              | Commercial kits                 | Simple; fast isolation                         | Lack specificity; much contamination; high price                             | Isolation of exosomes from serum and/or plasma                | [56]     |
| Novel techniques              |                                  |                                                 |                                                                                |                                                                  |----------|
| Immunoaffinity Enrichment     | Antibody-conjugated platform     | Simple; specificity                             | High-cost; marker dependent                                                  | Enrichment of exosomes from clinical samples                  | [20, 58, 70] |
| Magnetic Separation           | Antibody-modified magnetic beads | Convenient; high efficiency                    | High-cost; marker dependent                                                  | Separation of exosomes                                          | [36, 71–74] |
| Physical Feature-based separa-| Nanoscale lateral displacement   | Reduced membrane blockage; gentle processing   | Contamination of same-sized vesicles; lack specificity                         | On-chip sorting and quantification of exosomes                | [75]     |
| tion                          | Membrane filter                 | Gentle processing                               | Contamination of same-sized vesicles; lack specificity                        | On-chip isolation of intact extracellular vesicles              | [62, 76, 77] |
|                               | Deterministic lateral displacement| Continuous accurate and precise separation    | Low throughput and the requirement of high voltage                           | Efficient isolation of extracellular vesicles                  | [75, 78] |
|                               | Size-exclusion chromatography    | High yield; gentle processing                   | Contamination of same-sized vesicles; lack specificity                        | Efficient isolation of extracellular vesicles                  | [50, 52, 79] |
| Lipid Mediated-Separation     | Lipid nanoprobe/TiO₂              | Minimal damage                                  | Contamination of other phospholipid membrane vesicles; lack specificity       | Efficient isolation of extracellular vesicles                  | [66, 80] |
| Acoustic-based microfluidics  | Acoustic radiation force (ARF)   | Contact-free; high-throughput; continuous separ-| Design and fabrication finer gradations; finer-grade separation of subpopula- | Active sorting of extracellular vesicles                       | [67, 81] |
|                              | and dielectrophoretic (DEP)      | ations; wide range of particles                 | tion                                                                           |                                                                 | [68, 69] |
| Thermophoretic Enrichment     | Thermophoresis                   | Free from pre-isolation; simple; fast isolation | Contamination of same-sized vesicles; lack specificity                        | Efficient isolation of extracellular vesicles                  | [68, 69] |

(ExoDIF) device [59]. The biotinylated anti-CD63 antibody was immobilized on the surface of inner channel that sequentially pretreated with 3,3′-dithiobis(sulfosuccinimidyl)propionate (DTSSP), biotinylated BSA, and avidin. As a result, nearly 87.1% of exosomes were captured from high dilution of cell culture media. Notably, the captured exosomes could be dissociated by DTT (dithiothreitol) through breaking the embedded disulfide bond of DTSSP (Fig. 3A).

Recently, EVs on demand chip (EVOD) was proposed by Kang et al., in which the capture of cancer-related exosome subpopulations was achieved by the reaction between tetrazine-conjugated anti-EpCAM/anti-EGFR antibody (TzAb) and TCO (trans-cyclooctene) functionalized microfluidic surface [82]. This chip was able to selectively isolate 76% more EGFR+ exosomes from cancer patients than that from healthy donors, which exhibited great potential for the early detection of NSCLC. Sun et al. designed an interesting covalent chemistry-mediated EV click chip to recognize, enrich, and recover hepatocellular carcinoma (HCC)-specific exosomes from plasma samples by multi-marker cocktail (anti-EpCAM, anti-ASGPR1 (asialoglycoprotein receptor 1), anti-CD147) [61] (Fig. 3Ac). The proposed exosome purification system achieved more than 81% of recovery yield and more than 85% of purity, providing a novel liquid biopsy tool to detect hepatocellular carcinoma. Despite great significance, these methods are high-cost and marker-dependent. In addition, more attention should be paid to the non-destructive release of captured exosomes.

**Magnetic separation and enrichment**

Magnetic bead-based immunoaffinity enrichment has attracted much attention in recent years due to the advantages of convenience and high efficiency (Fig. 3A). Generally, exosomes are captured by antibody-modified magnetic beads, which are then separated by magnetic force. For example, Fang et al. conducted CD63 antibody-conjugated magnetic nanoparticles to isolate exosomes [71]. Moreover, novel immuno-affinitive superparamagnetic nanoparticles (IS-NPs) were proved to possess high efficiency, which combined anti-CD63 antibodies with superparamagnetic nanoparticles through the interactions between β-cyclodextrin (β-CD) and 4-aminooazobenzene (AAB) [60] (Fig. 3A). α-CD, a competitive agent extracting AAB from the β-CD-AAB inclusion compound, was adapted for the elution of exosomes. As a result, the capture and release efficiency of exosomes from artificial model samples was as high as 80% and 86.5%, respectively. IS-NPs method exhibited higher yield, increased purity and well-retained structural and functional integrity of exosomes than conventional separation methods.

The isolation of exosome subsets, especially cancer-derived exosomes, could be achieved by coupling magnetic beads with antibodies targeting specific biomarkers. Luo et al. performed a rapid separation and capture of exosomes by immunoaffinity magnetic beads and DNA origami-based aptamer. The quantitative detection of exosomes could be achieved through the combination with DNA fluorescence probe [83]. Li et al. developed a homogenous magneto-fluorescent exosome (hMFEX) nanosensor to separate GPC-1 positive exosomes in 80 μL of plasma from breast cancer patients [84]. He et al. conducted a microfluidic platform to capture tumor-derived exosomes by mixing samples with anti-EpCAM or anti-CA125 antibodies-labeled magnetic beads [36]. In general, the immunomagnetic separation methods hold the potential to facilitate rapid separation and clinical implication of circulating exosomes in desired areas.

**Physical feature-based separation**

Size-based microfluidic chip was used to separate exosomes from large cell debris or other membranous vesicles [76, 85] (Fig. 3B). Liu et al. designed a size-based exosome total isolation chip (ExoTIC) in which exosomes ranging in 30-200 nm were enriched and purified by multiple nanoporous membranes [62] (Fig. 3B). Compared with ultracentrifugation and commercial PEG precipitation kits, ExoTIC obtained much higher yields of exosomes from small volumes of human plasma. However, the blockage of membrane pores greatly limited the continuous separation of exosomes. To overcome this problem, Chen et al. introduced an ultrafast-isolation system, EXODUS, which integrated double coupled harmonic oscillations into a dual membrane filter configuration. By periodic negative pressure and air pressure switching, periodic negative pressure oscillations were generated on the nanoporous anodic aluminum oxide membrane, allowing small particles (i.e., proteins and nucleic acids) and fluids to pass through, while larger exosomes remained in the central chamber. Moreover, two pairs of oscillators enabled the resuspension of particles into the liquid via transverse waves and acoustofluidic streaming, which effectively limited fouling and particle aggregation [86]. In addition, tangential flow filtration (TFF) is a technology that effectively reduces the potential of pore clogging due to the perpendicular state of flow direction and filtration direction. Sunkara et al. developed a microfluidic tangential flow filtration device, Exodisc, to separate exosomes from human plasma and urine, which showed better exosome yield compared to conventional methods [63] (Fig. 3B). Deterministic lateral displacement (DLD) has been used for
exosome separation since particles with different sizes perform distinct trajectories in a platform with certain angle-displayed micropillars. Wunsch et al. proposed a nanoscale lateral displacement (nano-DLD) array, in which larger vesicles laterally displaced across the array and were collected at a side channel while smaller vesicles flew out of the array in a zigzag mode, finally achieving the collection of urine-derived exosomes [75]. However, DLD was limited by low throughput and the requirement of high voltage and the density and stiffness of vesicles may interfere with DLD-based exosome isolation.

**Lipid-based separation**

Lipid molecules on the surface of vesicles enable affinity-mediated exosome capture (Fig. 3C). Wan et al. reported a lipid nanoprobe for the rapid separation of exosomes from plasma [80]. The lipid bilayer of exosome was labeled with biotin-tagged 1,2-distearoyl-sn-glycero-3-phosphethanolamine-poly (ethylene glycol) (DSPE-PEG) probes in which DSPE was inserted into the exosome membrane by hydrophobic effect and PEG provided solubility in the aqueous phase. NeutrAvidin-coated magnetic sub-micrometer particles were used for the collection of exosomes through avidin-biotin affinity. As a result, it took only 15 min to isolate exosomes, which greatly shortened the isolation procedure [87]. Notably, cholesterol-PEG1000 of ~ 6.4 nm was considered to minimize steric hindrance in surface immobilization of lipid nanoparticles and thus achieved a much higher capture efficiency. Additionally, molecules absorbed to lipids on exosome membrane have also been applied to capture exosomes [88]. T-cell membrane protein 4 (Tim-4), which has high affinity to phosphatidylserine (PS), has been verified to facilitate simple exosome separation from serum samples, making it easier for rapid downstream analysis [65, 89] (Fig. 3C). In addition, the affinity interaction of TiO2 shell and phosphate groups of exosomes is a novel strategy for the enrichment of phosphorylated peptide. Pang et al. used Fe3O4@TiO2 nanoparticles to enrich and separate exosomes within 5 min with a capture efficiency of 96.5% [90]. The combination of Fe3O4@TiO2 nanoparticles and surface-enhanced Raman scattering (SERS) tags could enrich exosomes and achieve in-situ qualification of target miRNAs simultaneously [66] (Fig. 3C).

**Acoustic-based isolation method**

Acoustic-based microfluidics is a simple and efficient method for exosome separation. Typically, ultrasonic waves are applied to samples and the particles undergo different forces and are separated depending on their physical properties such as size and density [81] (Fig. 3D). Anson et al. utilized the ultrasonic waves scattering between micrometer-sized seeding particles and nanoparticles in a resonant cavity to enrich exosomes. The integrated acoustic device enabled fast operation, non-contact and continuous separation of exosomes from urine and plasma samples [91]. Wu et al. developed an acoustofluidic platform for direct, label-free, and contact-free enrichment of exosomes from whole blood. The device integrated two separation modules, one of which was able to remove particles larger than 1 μm in diameter and the other one could isolate exosomes from larger microvesicles and other particles [92]. Recently, Gu et al. reported an acoustically driven spinning droplets device, in which slanted interdigitated transducers (IDTs) were used to allow nanoparticles to move according to the sound waves of varying frequencies. Particles of fixed size could be specifically concentrated by placing two droplets of different sizes next to each other. As a result, the method could isolate exosomes from 5 μL samples in less than 1 min [93]. In addition, Tayebi et al. combined acoustic radiation force (ARF) with dielectrophoretic (DEP), in which high frequency (>10 MHz) interdigital transducer was placed in the flow path to simultaneously generate ARF and dielectrophoretic force field. Particles in the medium presented lateral translation by the competition between fluid drag forces, ARF, and DEP force fields, resulting in an active separation of extracellular vesicles [67] (Fig. 3D).

**Thermophoretic enrichment**

Thermophoresis refers to a phenomenon that particles migrate from space with high-temperature areas via a temperature gradient induced by localized laser heating. To address the challenge of time-consuming isolation and purification procedures, Liu et al. developed a sensitive thermophoretic method to enrich tumor-derived exosomes. By using aptamers that targeted tumor-specific markers, thermophoresis could achieve rapid isolation and enrichment of exosomes from other components without exosome pre-isolation (Fig. 3D). The accumulation of exosomes produced an amplified fluorescence signal of aptamers, which enabled profiling of surface biomarkers of exosomes as well as detection of miRNAs [68] (Fig. 3D). Tian et al. performed a similar assay to analyze exosomes in 1 μL plasma, which offered a low-cost, sensitive method for liquid biopsy in metastatic breast cancer [69] (Fig. 3D).
Exosome characterization

As suggested in the Minimal information for studies of extracellular vesicles 2018 (MISEV2018), the identification of exosomes should include western blot verification of exosome-specific markers and at least two methods for characterization of single exosome [94, 95].

Visible characterization

Transmission electron microscopy (TEM) is considered as the common method to identify and characterize a single exosome with typically cup-shaped structure (Fig. 4A) [62]. For scanning electron microscopy (SEM), images are presented by collecting the electrons ejected from the samples (Fig. 4C) [96]. Notably, the morphology of exosomes may be affected by dehydration during sample handling procedures. On the contrary, cryo-electron microscopy (cryo-EM) is a better choice because it avoids sample fixation and dehydration. Exosomes are analyzed at a very low temperature and exhibit a round structure that is different from TEM images [97] (Fig. 4B). In addition, atomic force microscopy (AFM) could provide information on both surface morphology and material properties (stiffness, adhesion) by amplitude modulation and phase modulation [96] (Fig. 4D). Moreover, specific exosome membrane markers functionalized AFM tips permit the identification and detection of proteins in single exosome [96, 98].

Quantitative characterization

Dynamic light scattering (DLS) is a technique for measuring the distribution of exosome size and zeta potential. The changes of scattered light interfere and intensity can be identified by a sensor, allowing for estimating the size distribution of particles [100–102] (Fig. 4E). However, the contamination of protein aggregates and large vesicles makes it challenging for DLS to distinguish them from exosomes [103]. Nanoparticle tracking analysis (NTA) is a widely used method for determining the concentration and size distribution of particles (Fig. 4F). Particles are illuminated by a beam of light and the scattering light...
signals are collected by optical microscope [100, 104]. Tunable resistive pulse sensing (TRPS) detects the electrical signals generated by changes in ion conductivity when exosomes pass through pores filled with conductive media [105] (Fig. 4G).

**Techniques for detecting exosome contents**

**Conventional protein analysis**

Both membrane and cytoplasmic proteins could be detected in exosomes [4]. Some membrane proteins on exosomes are involved in cancer development and progression and thus have been used as targets for exosome isolation and purification [28, 106]. Western blot and enzyme-linked immunosorbent assay (ELISA) are two regular approaches widely used to detect exosomal proteins [7, 107]. However, these methods are faced with complex procedure and low sensitivity problems [108].

**New protein detection methods**

**Colorimetric detection**

Up to now, multiply novel techniques have been developed to detect exosomal proteins (Table 2). Colorimetric detection is a method to determine the content of a component by comparing or measuring the color intensity of chromogenic substances (Fig. 5A). Similar to other nanomaterials like Fe3O4 NPs and AuNPs, DNA has the ability of significantly increasing the peroxidase activity of single-walled carbon nanotubes (s-SWCNTs). Xia et al. developed a visible and simple method for the detection of exosomes [109]. Briefly, CD63 aptamer improved the minic peroxidase activity of s-SWCNTs and effectively catalyzed oxidation of 3,3′,5,5′-tetramethylbenzidine (TMB), resulting in a colorless solution turning blue. On the contrary, the addition of exosomes induced the release of aptamer from the surface of nanotubes and the color of solution to turn from dark to light, which could be observed by naked eye or UV-visible spectrometry with a detection limit (LOD) of 5.2 × 10⁵ particles/μL. As previously discussed, ZnO-chip was designed to effectively isolate exosomes. After incubation with primary antibody mixture (anti-CD9/CD63 antibody), exosomes were recognized by HRP (horseradish peroxidase)-labeled secondary antibody (Fig. 5A). Finally, a minimal detectable concentration of 2.2 × 10⁴ particles/μL was obtained by UV-visible spectrometry or microplate analyzer [110]. Liang et al. designed a microfluidic system integrated with double membrane filter and ELISA to detect the content of exosomes in urine samples of bladder cancer patients [111]. In addition to common exosomal proteins, colorimetry could be applied to detect cancer-specific proteins as well. For instance, a PSA (prostate-specific antigen) aptamer-based sensor was used for the visual detection of prostate cancer-specific exosomes in 500 μL human plasma [72]. Moreover, Di et al. reported a nanozyme-assisted immunosorbent assay (NAISA), which enabled sensitive and rapid multiplex profiling of exosomal proteins [112] (Fig. 5A). The surface proteins of exosomes could be specifically captured by antibodies immobilized on the surface of a microplate and catalyzed a colorimetric reaction. Signal intensity obtained from microplate reader is proportional to the number of target proteins. As a result, NAISA allowed the rapid profiling of multiple exosomal proteins such as CD63, CEA (carcinoembryonic antigen), GPC-3 (Glypican-3), PD-L1 (programmed death-ligand 1), and HER2 (human epidermal growth factor receptor 2) from clinical samples.

**Fluorescence detection**

Fluorescence spectrophotometry is a method for substance identification and content determination according to the positivity and intensity of fluorescence spectral line (Fig. 5B). He et al. conducted a microfluidic chip to detect surface and intravesicular biomarkers from 30 μL plasma samples. This chip obtained a markedly improved detection sensitivity of IGF-1R (type 1 insulin growth factor receptor), 0.281 pg/mL of IGF-1R and 0.383 pg/mL of p-IGF-1R, which was 100-fold higher than that achieved by ELISA [36] (Fig. 5Ba). Liu et al. developed an immunosorbent assay, in which immunomagnetic beads were utilized to capture exosomes, followed by the conjugation of an enzymatic reporter, which could produce a fluorescent signal for quantititation of GPC-1⁺ exosomes in the droplet microfluidic system [124]. Wei et al. proposed similar single molecule array (SiMoa) platform, by which universal exosomes and tumor-derived exosomes could be ultrasensitively detected with an LOD of 34 particles/μL and 25 particles/μL, respectively [125]. Yu et al. conducted a CD63 aptamer-based detection method. CD63 on exosomes could bind to aptamers modified on the surface of magnetic beads, resulting in the shedding of a Cy3-labeled short sequence into the supernatant. The fluorescence intensity in the supernatant was used to quantify exosomes in complex clinical samples [126].

Graphene oxide has the ability of quenching fluorescence via fluorescence resonance energy transfer (FRET) when conjugated with fluorescent dyes. For instance, the fluorescence of FAM-labeled aptamers was quenched when absorbed onto graphene oxide membranes, while target exosomes competitively bound to aptamers and re-exhibited fluorescent signals with an LOD of 1.6 × 10⁵ particles/mL [113] (Fig. 5B). Li et al. developed a facile fluorescent aptasensor based on aggregation-induced emission luminogens (AIEgens). Graphene oxide absorbed (tetrafluorene-containing tertiary amine) TPE-TAS/aptamer complex allowed fluorescence quenching
| Methods               | Exosome sources                          | Sample volume | Sensing mechanism                             | Sensing substances                                                                 | Detection limit          | Ref. |
|-----------------------|------------------------------------------|---------------|-----------------------------------------------|------------------------------------------------------------------------------------|--------------------------|------|
| Colorimetric Detection | MCF-7 cells and breast cancer patient's serum | 500 μL        | $H_2O_2$-mediated oxidation of TMB             | s-SWCNTs; CD63-specific aptamer                                                    | $5.2 \times 10^5$ particles/μL | [109]|
|                       | Cell-culture medium and prostate cancer patient's plasma | 500 μL        | $H_2O_2$-mediated oxidation of TMB             | Aptamer-capped Fe$_3$O$_4$ nanoparticles                                             | $3.58 \times 10^6$ particles/μL | [72]|
|                       | Urine                                    | 100 mL        | $H_2O_2$-mediated oxidation of TMB             | Biotinylated anti-CD63 antibody; streptavidin-labeled HRP                           | 35 AU/mL                 | [76]|
| Fluorescence Detection | MCF-7 cells and cancer patient's serum | 100 μL        | $H_2O_2$-mediated oxidation of TMB             | CD9, CD63 antibody mixture; HRP-labeled secondary antibody                          | $2.2 \times 10^3$ particles/μL | [110]|
|                       | BeWo cell                                | 100 μL        | $H_2O_2$-mediated oxidation of TMB             | Au-NP; Fe$_3$O$_4$ NC                                                              | $10^3$ exosomes/mL        | [148]|
|                       | Plasma specimens from NSCLC and OVCA patients | 30 μL        | Chemifluorescence reagents                     | EpCAM, IGF-1R or CA125 antibodies; AP-conjugated secondary antibody, and the DFMUP substrate | $0.281$ pg/mL; $0.383$ pg/mL | [36]|
|                       | SKOV3 cells and plasma of OVCA patients | 10 μL         | The reaction of SβG with FDG                   | Biotin conjugated detection antibodies and streptavidin conjugated SβG              | 21 exosomes/μL            | [149]|
|                       | MCF-7 and MDA-MB-231 cell culture medium | 1 mL          | Fluorescent carbocyanine dye (DiO)             | CD63 antibody-functionalized microbead and DiO labelling                            | CD63 antibody-functionalized EXOchip | [20]|
|                       | Cell culture supernatant and serum from pancreatic cancer patients | 1 mL          | Fluorescent carbocyanine dye (DiO)             | CD63 antibody-functionalized microbead and DiO labelling                            | CD63 antibody-functionalized EXOchip | [20]|
|                       | MCF-7 cells and blood samples from cancer patients | 100-300 μL   | Fluorescent second antibody                    | Anti-EpCAM antibody and Alexafluor®647-conjugated secondary antibody                | CD63 antibody-coated magnetic beads; fluorescent dye-conjugated antibodies | $10^3$ particles/μL | [151]|
|                       | Cell culture medium and plasma from breast cancer patients | 1 mL          | Fluorescent second antibody                    | Anti-EpCAM antibody and Alexafluor®647-conjugated secondary antibody                | CD63 antibody-coated magnetic beads; fluorescent dye-conjugated antibodies | $10^3$ particles/μL | [151]|
|                       | A549 cancer cell line and plasma samples of lung cancer patients | 0.5 μL       | Fluorescent aptamer                            | TMR-aptamer                                                                        | 500 particles/μL          | [152]|
|                       | Serum samples                            | 500 μL        | Fluorescent aptamer                            | CD63 aptamer-modified magnetic beads; Cy3-labeled short sequence                   | $1.0 \times 10^5$ particles/μL | [126]|
|                       | Cancer cell line and plasma samples       | 80 μL         | Fluorescent aptamer                            | TPE-TAs/aptamer complexes; graphene oxide surface                                   | $3.43 \times 10^5$ particles/μL | [99]|
|                       | MDA-MB-231 cell culture medium and plasma from breast cancer patients | 80 μL         | Fluorescent quenching                          | GPC-1 antibody coated magnetic beads; CD63 aptamer                                  | $6.56 \times 10^4$ particles/μL | [84]|
|                       | Cancer cell line and serum samples        | 80 μL         | Fluorescent quenching                          | FAM-labeled aptamers; graphene oxide                                               | $1.6 \times 10^4$ particles/mL | [113]|
|                       | Cancer cell line and blood samples        | 80 μL         | Fluorescent quenching                          | Anti-CD63-PE/MoS2–MWCNT                                                            | $14.8 \times 10^4$ particles/mL | [153]|

Yu et al. Molecular Cancer (2022) 21:56

Page 11 of 33
| Methods | Exosome sources | Sample volume | Sensing mechanism | Sensing substances | Detection limit | Ref. |
|---------|----------------|---------------|-------------------|-------------------|----------------|-----|
| Electrochemical Detection | Ovarian cancer cell lines and plasma from patients with ovarian cancer | 10 μL | Integrated magneto-electro-chemical sensor | Immunomagnetic beads; HRP-labeled secondary antibody | $3 \times 10^4$ | [128] |
| Plasma samples | 20 μL | Electrochemical biosensor | Immunomagnetic beads; probing antibodies | | | [129] |
| Cell-culture medium and blood samples from breast cancer patients | | | | | | [144] |
| HepG2 cells and human serum of liver cancer patients | 30 μL | Aptamer-based biosensors | Anti-PD-L1-linked DNA strand; PVP@HRP@ZIF-8 | 334 particles/mL | | [114] |
| Culture medium of HepG2 cells | | | | | | |
| Cell-culture medium and serum | | | | | | |
| Cellular supernatant and human plasma samples | | | | | | |
| Human hepatoma cell lines MHCC97H/L and mouse melanoma cell lines B16-F1/10 | | | | | | |
| Methods                      | Exosome sources                                                                 | Sample volume | Sensing mechanism                        | Sensing substances                                                                                           | Detection limit | Ref.   |
|------------------------------|---------------------------------------------------------------------------------|----------------|------------------------------------------|-------------------------------------------------------------------------------------------------------------|----------------|--------|
| SPR Detection                | MCF-7 breast cancer cells and MCF-10A normal breast cells                       | 1.5 mL         | SPR-based aptasensor                     | Dual gold nanoparticle-assisted signal amplification                                                           | $5 \times 10^3$ exosomes/mL | [158] |
|                              | Human NSCLC cell lines, normal lung cell and plasma                              |                | Bioaffinity interactions of antibodies and different recognition sites | Antibodies modified-gold chip and different recognition sites                                               | $10^4$ particles/μL | [159] |
|                              | Urine samples from lung cancer patients and controls                             | 500μL          | SPR-induced improved scattering intensity | Anti CD81/URG1 antibody modified nanoporous gold nanocluster membrane; second antibody-conjugated Au nanorod probes | < 1000 particles/mL | [58]  |
|                              | Breast cancer cell line and serum                                               | 250μL          | SPR-induced improved scattering intensity | Anti-HER2-functionalised SPR chip                                                                             | 8280 exosomes/μL | [160] |
|                              | Cancer cells and serum and the CSF of an orthotopic mouse model                  |                | Strong localization of surface plasmon polaritons | TIC-AFM and TiN–NH-LSPR biosensors                                                                            | $5.29 \times 10^{-1}$ μg/ml; $3.46 \times 10^{-3}$ μg/ml | [161] |
|                              | Breast cancer cells and normal breast cells; plasma from HER2-positive breast cancer patients |                | Raman reporters                          | Gold-coated glass microscopy slide; QSY21-coated gold nanorods                                                | $2 \times 10^9$/μL | [117] |
| SERS                         | Plasma of cancer patients                                                        | 400μL          | P-O bond signature                       | Beehives-like Au-coated TiO$_2$ macroporous inverse opal                                                      | 1 PD-L1 exosome/μL | [90]   |
|                              | Cell-culture medium and serum sample                                             | 4μL            | MBA signature                            | Fe$_3$O$_4$@TiO$_2$ nanoparticles; anti-PD-L1 antibody modified Au@Ag@MBA                                    |                |        |
|                              | Normal and lung cancer cell lines; plasma                                        |                | Deep learning                            | Deep learning model                                                                                         |                |        |
|                              | Cell-culture medium; serum and plasma                                            | <1 μL          | Enrichment of aptamer-bound EVs          | Seven aptamers targeting specific proteins; machine-learning algorithm                                        | $3.3 \times 10^3$/μl | [68]   |
| CRISPR/Cas-assisted detection | A549 cell-culture medium and serum from lung cancer patients                    |                | CRISPR/Cas1 2a                          | CD63 aptamer; CRISPR/Cas12a                                                                                   | Linear range of $3 \times 10^3$–$6 \times 10^7$ particles/μL | [136] |
|                              | SUNE2 cell-culture medium and serum from NPC patients                           | 50μL           | CRISPR/Cas1 2a                          | Nucleolin and PD-L1 aptamers; CRISPR/Cas12a                                                                 | $10^2$ particles/μL | [137] |
|                              | SUNE2 cell-culture medium and serum from NPC patients                           |                | CRISPR/Cas1 2a                          | CD109 and EGFR aptamers; CRISPR/Cas12a                                                                       | $10^2$ particles/μL | [138] |
| Methods                        | Exosome sources                        | Sample volume | Sensing mechanism            | Sensing substances                                                                 | Detection limit | Ref. |
|-------------------------------|----------------------------------------|---------------|------------------------------|------------------------------------------------------------------------------------|----------------|------|
| Single EV Analysis            | Human serum                            | 10 μL         | Rolling circle amplification | ssDNA-assisted single EV detection platform                                        | 82 vesicles/μL  | [139]|
| T3M4 pancreas cancer line and | 10 mL Flow cytometry                    |               |                              | Aldehyde/sulfate latex beads; anti-GPC-1 antibody and Alexa-488-tagged antibody     |                | [38] |
| serum from PDAC patients      |                                        |               |                              |                                                                                     |                |      |
| Breast cancer cell lines and  | 500 μL Flow cytometry                    |               |                              | Aldehyde/sulfate latex beads; anti-EpCAM or anti-HER2 antibody; Alexa-488- or —   |                | [141]|
| serum of breast cancer patients|                                        |               |                              | 594-tagged secondary antibodies                                                     |                |      |
| Human cell lines and serum of | 250 μL Flow cytometry                    |               |                              | Aldehyde/sulfate latex beads; anti-EGFR or anti-CXCR4 antibody                      |                | [118]|
| glioma patients               |                                        |               |                              |                                                                                     |                |      |
| HCT15 cell-culture medium and | 500 μL Nano-flow cytometry              |               |                              |                                                                                     |                | [142]|
| plasma                        |                                        |               |                              |                                                                                     |                |      |

OVCA Ovarian cancer, PGR Progesterone receptor, ESR1 Estrogen receptor 1, ERBB2 erb-b2 receptor tyrosine kinase 2
in the absence of exosomes. When target exosomes were introduced, the aptamer preferentially bound to its target, resulting in the separation of the TPE-TAS/aptamer complex from the graphene oxide surface, followed by a “turn-on” fluorescence signal. The linear range of tumor-derived exosomes was around $4.0 \times 10^5 - 1.8 \times 10^7$ particles/μL under optimized conditions [99].

**Electrochemical detection**

Electrochemical detection is used to detect the analytes by measuring the electrochemical potential or current of the sample, which has the advantages of high sensitivity and wide measurement range (Fig. 5C). In recent years, electrochemical biosensors have been developed by researchers since the altered electrochemical signals could quantify exosomes when recognition elements such as antibody and aptamer specifically bind to exosomes [127, 128]. Cao et al. proposed an electrochemical biosensor to accurately detect PD-L1⁺ exosomes [114] (Fig. 5C). Exosomes were firstly captured by anti-CD63 functionalized magnetic beads and then bound with anti-PD-L1-linked DNA strand, introducing a...
hyperbranched rolling circle amplification (HRCA). The HRCA could decrease the environmental pH, leading to the decomposition of PVP@HRP@ZIF-8 and release of HRP, which resulted in amplified electrochemical responses and thus achieved the identification and detection of cancer-derived PD-L1+ exosomes. This biosensor displayed a wide dynamic range for PD-L1+ exosomes ($1 \times 10^3$ to $1 \times 10^{10}$ particles/mL) and the detection limit was 334 particles/mL. Jeongmin et al. reported a HiMEX approach which integrated magnetic exosome separation and electrochemical detection of exosome-bound proteins after enzymatic amplification. The combined detection of tumor biomarkers (EGFR, EpCAM, CD24 and GPA33) in exosomes from 20 μL plasma samples were helpful for the diagnosis and monitoring of colorectal cancer [129]. Electrochemical methods, especially aptamer-based biosensors have shown great potential in the detection and profiling of exosomal proteins [65]. Kashefi-Kheyrabadi et al. introduced a detachable microfluidic device implemented with an aptamer-based electrochemical biosensing method (DeMEA). In this system, aptamer targeting EpCAM was immobilized on the electrode surface that was pre-electroplated with gold nanostructures and microfluidic vortexes could increase the collision between exosomes and sensing surface (Fig. 5C). Consequently, DeMEA was able to quantify exosomes from plasma samples of breast cancer patients at different stages, which provides a highly sensitive and early detection of cancer-specific exosomes [115].

**Surface plasmon resonance detection**

Surface plasmon resonance (SPR) is a physically optical phenomenon caused by total reflection of light at the metal film/liquid level interface to analyze molecular interactions (Fig. 5D) [130, 131]. Im et al. developed a nano-plasmonic exosome (nPLEX) assay based on transmission SPR through periodic nanohole arrays (Fig. 5D). With functionalized antibodies in each array, the nPLEX sensor displayed spectral shifts or intensity changes that were proportional to the levels of target exosomal proteins [116]. In another study, the markedly improved scattering wavelength shift and scattering intensity were observed on AuNC-Exosome-AuR due to the plasmon effect [58]. The differential expression of LRG1 (leucine rich alpha-2-glycoprotein 1) in urinary exosomes between lung cancer patients and healthy individuals was evaluated by anti-LRG1 antibody-conjugated AuR probes. Another surface plasmon resonance imaging (SPIRI)-based biosensing assay was developed by Fan et al. The bioaffinity interactions between antibodies (anti-CD63/anti-EGFR/anti-EpCAM) modified-gold chip and different recognition sites permitted the multiplex characterization of NSCLC-derived exosomes. The LOD of this biosensor was estimated to be $10^4$ particles/μL. Despite multiple merits, the broad applications of nanoplasmonic biosensors are restrained by the difficult fabrication of nanostructures. To address this challenge, Liu et al. developed an intensity-modulated SPR biosensor free from nanostructure. In this sensor, the reflection intensity and reference intensity of lasers were recorded by two photodetectors and were used to quantify the expression levels of exosomal proteins, which exhibited a higher detection sensitivity than ELISA [132].

**Surface enhanced Raman scattering**

Surface enhanced Raman scattering (SERS) is capable of enhancing the Raman signal of small molecules attached to the rough metal surface through electromagnetic and chemical mechanisms [133] (Fig. 5D). A new assay was reported for the real-time detection and protein profiling of exosomes. Generally, gold-plated slides combined with 3D-printed antibody arrays were fabricated to capture exosomes, and QSY21-coated gold nanorods were used as the label agent to quantitatively detect target proteins. The levels of plasma-derived exosomes of breast cancer patients were quantitatively determined by using this assay targeting HER2 and EpCAM. The proposed 3D-printed array template enabled cheap, portable, and easily available establishment of detection platform, providing a new strategy for the development of novel cancer liquid biopsy [134]. Dong et al. showed that the analysis of protein phosphorylation status may provide new possibilities for cancer diagnostics [117] (Fig. 5D). A beehives-like Au-coated TiO$_2$ macroporous inverse opal structure was developed to capture and analyze exosomes without any labeling process. The intensity of 1087 cm$^{-1}$ SERS peak referred to the P-O bond within the phosphoproteins of exosomes and the intensity of peak was at least two times from plasma of cancer patients than that from healthy donors. However, the above-mentioned two assays both require the pre-separation of exosomes, which greatly hinders the rapid analysis. Pang et al. presented a simple immunoassay to capture and analyze exosomal PD-L1 directly from serum samples [90]. Fe$_3$O$_4$@TiO$_2$ nanoparticles were designed to isolate exosomes and anti-PD-L1 antibody modified Au@Ag@MBA SERS tags were applied for exosomal PD-L1 labeling and SERS detection. This assay was confirmed to quantify exosomal PD-L1 in 4 μL serum sample within 40 min.

**CRISPR/Cas system-assisted detection**

In CRISPR/Cas9 system, the Cas9 nuclease could efficiently shear the double-stranded DNA (dsDNA) sequence by recognizing specific complementary dsDNA containing protospacer adjacent motif (PAM) sequences.
with the help of guide RNA (gRNA) [135]. Through aptamers that specifically target exosomal proteins, the detection of proteins could be transformed into the quantification of nucleic acids. Recently, Zhao et al. reported a detection method which combined aptamer-based exosomal membrane protein recognition with CRISPR/Cas12-assisted fluorescence signal amplification [136]. In this system, CD63 aptamer specifically targeted exosome membrane proteins, triggering the conformational change of aptamer and release of blocker strands (with complementary sequences to aptamer). The released blocker was then recognized by CRISPR/Cas12a, resulting in the trans-cleavage toward TaqMan probe and the separation of fluorescence reporter group and quenching group, finally leading to the generation of amplified fluorescence signal. As a result, this method achieved a linear detection range of $10^3$-$10^7$ particles/μL and was successfully applied in the direct detection of plasma exosomes without ultracentrifugation. Xing et al. developed an apta-HCR-CRISPR assay to detect circulating nucleolin$^+$ or PD-L1$^+$ exosomes from 50μL serum of nasopharyngeal carcinoma cancer (NPC) patients [137]. Nucleolin or PD-L1-targeted aptamer was first amplified by HCR (hybridization chain reaction) to produce a long-repeated CRISPR-targetable DNA unit. Through collecting the fluorescence signal induced by collateral cleavage activities of CRISPR-Cas12a, the assay enabled a detection limit of $10^2$ particles/μL. A similar assay was conducted by Li et al. for the ultrasensitive detection of CD109$^+$ and EGFR$^+$ exosomes [138]. CRISPR/Cas system is expected to be a sensitive tool for the identification and quantification of exosomal proteins and may contribute to the diagnosis and therapeutic monitoring of cancer.

**Single exosome detection**

Intrinsic heterogeneity is one of the main factors hindering exosome analysis in body fluids. Single exosome detection may provide more accurate information of tumor progression (Fig. 5E). Guo et al. presented an ssDNA-assisted single exosome detection platform. Rolling circle amplification (RCA) was used to amplify fluorescent signal from the surface protein, enabling easy visualization of individual exosomes with an LOD of 82 vesicles/μL [139]. In addition, Liu et al. developed a λ-DNA and aptamer-mediated approach, allowing for two-dimensional analysis of single exosome by size and tumor-associated marker expression [140]. Since nanosized exosomes cannot be sensitively identified by conventional flow cytometry, aldehyde/sulfate latex beads have been used to bind to vesicles, which are then stained with fluorescent antibodies and characterized for their protein markers. For example, anti-GPC-1 antibody and Alexa-488-tagged secondary antibody were introduced to the exosome-attached beads and the percentage of positive beads was therein referred as the percent of GPC-1$^+$ exosomes [38]. In addition, the detection of expressed EpCAM, HER2 and EGFR in exosomes indicated their potential role in cancer diagnostics [118, 141] (Fig. 5E). Moreover, the development of nano-flow cytometry has provided a new option for multi-parameter analysis of single particle. The expression of CD9, CD63, CD81, CD235a, CD45, CD41a and CD144 of single exosome was measured using immunofluorescent labelling using nano-flow cytometry to evaluate the quality of exosome preparations isolated by six different methods. Liu et al. used nano-flow cytometry to analyze the expression of CD9, CD63, CD81, CD47, CD45, CD24, and EpCAM in tear-derived exosomes and found that the exosome concentration in tear fluid was approximately 100-fold higher than that of plasma exosomes [142].

**Conventional nucleic acids analysis**

In addition to protein cargoes, nucleic acids are encapsulated in exosomes as well. RNAs represent the major nucleic acid cargo of exosomes, which have shown the potential to be specific biomarkers for cancer diagnosis and prognosis prediction [2, 143, 144]. Nevertheless, the accuracy and feasibility of detecting exosomal nucleic acids are often hampered by their low abundance. To quantify the expression levels of exosomal nucleic acids, techniques such as qRT-PCR (real-time quantitative reverse transcription PCR), microarray, and next-generation sequencing (NGS) have been used. Despite high sensitivity, qRT-PCR can only be used to detect nucleic acids with known sequences [145]. NGS is beneficial for high-throughput discovery and quantitation of unknown exosomal RNA transcripts. However, shortcomings such as high cost, huge amount of data and complexity of building libraries need to be addressed [146]. Through the complementary combination of hybridized probes and target genes, microarrays can analyze thousands of nucleic acids in exosomes at one time but have the disadvantages of low sensitivity [147]. To overcome these limitations, more efforts are being devoted to developing highly sensitive and convenient methods for exosomal nucleic acid detection (Table 3).

**New nucleic acids detection technologies**

**ddPCR**

Droplet digital PCR (ddPCR) is a technique in which the PCR reaction mixture is divided into tens of thousands of aqueous droplets in an oil emulsion (Fig. 5F). Each single droplet contains no more than one copy of target gene and is labeled as positive or negative according to the fluorescence amplitude. The concentration of target nucleic acids is then estimated by the Poisson
| Methods               | Exosome sources                          | Sample volume | Nucleic acids                              | Detection mechanism                                      | Advantages                                                                 | Disadvantages                                                                 | Ref.  |
|----------------------|------------------------------------------|---------------|--------------------------------------------|---------------------------------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------|-------|
| Droplet digital PCR  | Urine                                    | 2 mL          | miRNA; gene variation                      | Nucleic acid amplification of droplets in an oil emulsion | Absolute quantification; small sample volume; high accuracy and sensitivity; | High-cost; limited throughput; complex operation                              | [163] |
|                      | Cerebrospinal fluid of GBM patients      | 1 mL          | IDH1 mutation                              |                                                         |                                                                             |                                                                                | [164] |
|                      | Plasma samples of HCC patients and control cohorts | 90 μL        | HCC-specific mRNA                          |                                                         |                                                                             |                                                                                | [61]  |
|                      | Cancer cell lines and patient plasma     | 2 μL          | GAPDH mRNA                                 |                                                         |                                                                             |                                                                                |       |
|                      | Human plasma                             | 2 μL          | miR-15a-5p; PGR mRNA; ESR1 mRNA; ERBB2 mRNA |                                                         |                                                                             |                                                                                | [40]  |
|                      | Clinical blood                           | 1.5 mL        | miRNA-21 Fluorescent, enzyme-labeled oligonucleotide probes identifying and detecting nucleic acid with complementary sequences | High specificity, simplicity; low background fluorescence; rapid detection |                                                                 | High-cost; limited throughput                                                  | [122] |
|                      | Serum                                    | 100 μL        | circHIPK3 and circSM ARCA5                 |                                                         |                                                                             |                                                                                | [167] |
| Molecular beacons    | Cancer cells and human sera              | 35 μL         | miRNA-21                                    |                                                         | Fluorescent, enzyme-labeled oligonucleotide probes identifying and detecting nucleic acid with complementary sequences | High specificity, simplicity; low background fluorescence; rapid detection | [121] |
|                      | Breast cancer cell line and human plasma | 35 μL         | miR-21; miR-375; and miR-27a                |                                                         |                                                                             |                                                                                |       |
|                      | Prostate cancer cells and human urine    | 10 μL         | miRNA-375 and miRNA-574-3p                 |                                                         |                                                                             |                                                                                |       |
|                      | Human plasma                             | 2 μL          | miRNA-451a; miRNA-1246                     |                                                         |                                                                             |                                                                                |       |
|                      | RBC-derived EVs                          | 100 μL        | miR-21                                     |                                                         |                                                                             |                                                                                |       |
|                      | PCA cell                                 | 1 mL          | miR-21; miR-1246; miR-221; miR-375; miR-211  | Leverage localized reaction and cascade amplification  | High specificity and sensitivity                                              | High-cost                                                                      | [171] |
| DNA tetrahedron probe| Serum                                    | 1 mL          | miRNA                                      |                                                         |                                                                             |                                                                                | [172] |
|                      | Plasma                                   | 50 μL         | miR-10b                                    |                                                          | The change of dielectric constant caused by molecule adsorption on the heavy metal film | High specificity and sensitivity; label-free                                 | [173] |
| SPR Detection        | Pancreatic cancer cells and plasma       | 50 μL         | miRNA                                      |                                                         |                                                                             | Nonspecific adsorption                                                         | [123] |
|                      | Plasma                                   | 10 μL         | miRNA                                      |                                                         |                                                                             |                                                                                | [174] |
|                      | Mouse serum                              | 1 mL          | miR-10b                                    |                                                         |                                                                             |                                                                                |       |
| Single Vesicle Analysis | Serum                                   | 100 μL        | hsa-miRNA-21                               |                                                         | Single-vesicle imaging; Direct visualization; acknowledgement of heterogeneity at the single-vesicle level | Nonspecific adsorption                                                      | [119] |
Table 3 (continued)

| Methods                          | Exosome sources | Sample volume | Nucleic acids | Detection mechanism                      | Advantages                                      | Disadvantages                         | Ref.    |
|----------------------------------|-----------------|---------------|---------------|------------------------------------------|------------------------------------------------|---------------------------------------|---------|
| Thermophoretic Detection         | Serum           | 0.5 μL        | miRNA         | Nanoflare induced amplified fluorescence signal | Without the need for EV pre-isolation; high sensitivity; rapid detection; low cost |                                      | [175]   |
| CRISPR/Cas-assisted detection    | Plasma          | 500 μL        | miRNA-21; miRNA-221; miRNA-222 | CRISPR/Cas9 | High sensitivity and specificity          |                                      | [176]   |

PGR Progesterone receptor, ESR1 Estrogen receptor 1, ERBB2 erb-b2 receptor tyrosine kinase 2, PCA76 Prostate cancer associated transcript 6
distribution and ratio of the positive droplets [177]. The comparison between ddPCR and qPCR showed that ddPCR had higher accuracy and sensitivity in analyzing urinary exosomal miRNAs [163]. Chen et al. used ddPCR to identify IDH1 (isocitrate dehydrogenase 1) transcripts in exosomes derived from serum or cerebrospinal fluid (CSF) of glioblastoma (GBM) patients. Mutant IDH1 mRNA was identified in CSF-derived exosomes of patients bearing mutant IDH1 glioblastoma and higher level of IDH1 mRNA was found in exosomes from patients with tumors than healthy controls [164]. Sun et al. recently used ddPCR to quantify 10 HCC-specific mRNA from plasma samples of HCC patients (Fig. 5F). The diagnostic value of HCC exosome-derived mRNA signatures was evaluated by computing the digital scoring [61]. Moreover, exosomal miR-15a-5p was detected by ddPCR to distinguish endometrial cancer (EC) patients from healthy subjects [40]. Shen et al. reported that more copy numbers of IncRNAs RP11-77G23.5 and PHEX-AS1 were quantified by ddPCR in EpCAM-specific exosomes from malignant lung cancer patients compared to benign lung tumors [178].

Molecular beacons

Molecular beacon (MB) is a hairpin-like oligonucleotide labeled with fluorescent dye and quencher at two ends of the probe (Fig. 5G). MB is designed to spontaneously hybridize with the targeted sequence, thereby destroying the hairpin ring structure and inducing the appearance of fluorescence [179]. Lee et al. observed that high fluorescent signals were obtained by the hybridization of molecular beacons and miRNA-21 in exosomes of cancer cells and human serum [122] (Fig. 5G). Moreover, miR-375 and miR-574-3p were detected from exosomes of human urine by MB-based biosensors [168]. The expression levels of miR-21, miR-375, and miR-27a were detected in exosomes of human serum [121] (Fig. 5G). Oliveira et al. utilized CPP (cell-penetrating peptides) to deliver MB across the plasma membrane and then to detect miRNA-451a in red blood cell (RBC)-derived exosomes [170]. Chen et al. designed a 2'-O-methyl and phosphorothioate modified molecular beacon to quantitatively analyze exosomal miRNA-1246 from human plasma. After rupturing the exosome membrane with Triton X-100, the probe could specifically target miRNA-1246 inside and display quantitative fluorescence signals [169]. Zhang et al. developed an integrated exosome isolation and detection system, in which exosomes could be separated by microfluidic technology via using a little volume of samples. Meanwhile, nanopore detection technology effectively improved the detection efficiency of tumor-related miRNA without the need for amplification and fluorescence labeling of detected objects [180]. The molecular beacon-based biosensor has the priority of simple procedure, free from exosome pre-isolation and nucleic acid extraction, indicating their great potential in liquid biopsy for cancer diagnosis and prognosis.

DNA tetrahedron probe

DNA tetrahedron, a DNA nanoarchitecture with high controllability, can provide diverse amplified signal tags through chemical modification and DNA self-assembly [181]. Gao et al. conducted a DNA tetrahedron nanoprobe-based FRET sensing platform to sensitively detect miR-146b-5p in different cell lines [182]. Chen et al. reported a hairpin-tetrahedron nanoprobe for quantitative measurement of exosomal miR-21 in human serum [171]. In the absence of miR-21, the construction of fluorophore donor-quencher pairs resulted in a low FRET effect, while the presence of target miRNA induced the damage of stem-loop structure and occurrence of strong FRET. Consequently, the assay obtained a good linearity in the range from $1 \times 10^{-12}$ to $10 \times 10^{-9}$ M (mol/L) and a detection limit of $45.4 \times 10^{-15}$ M. Zhang et al. proposed a similarly electrochemical biosensor based on two multifunctional DNA tetrahedrons assisted catalytic hairpin assembly. By leveraging localized reaction and cascade amplification, the sensor enabled sensitive detection of tumor-associated exo-miRNAs down to 7.2 aM in 30 min [172].

Localized surface plasmon resonance

Localized surface plasmon resonance (LSPR) occurs when the incident photon frequency matches the overall vibration frequency of precious metal nanoparticles or metal conducting electrons (Fig. 5H). Joshi et al. developed a biosensor based on LSPR for the label-free and nondestructive measurement of exosomal miR-10b [173]. Gold nanoprism were chemically synthesized onto a silanized glass substrate and then functionalized with HS-C6-ssDNA and PEG6-SH. The direct hybridization of target miR-10b and HS-C6-ssDNA induced the formation of double-strand DNA which could increase the index of refraction of nanoprism and change the wavelength of LSPR dipole peak ($\lambda_{LSPR}$). The concentration of miR-10b could be evaluated by $\Delta \lambda_{LSPR}$. This platform was sensitive enough to distinguish between miR-10b and miR-10a (only one nucleotide difference) even in the subattomolar concentration range. Wu et al. developed an SPRi-based biosensor to detect multiple exosomal miRNAs for accurate diagnosis of NSCLC, in which Au-on-Ag heterostructure and DNA tetrahedral framework were utilized to enhance SPR signal and each exosomal
miRNA could be ultrasensitively identified with different SPR signals [123] (Fig. 5H,
)

TIRF-based single-vesicle imaging
As a single-exosome analytic method, total internal reflection fluorescence (TIRF) has emerged for providing additional information about the heterogeneity of exosomes (Fig. 5E). He et al. proposed a TIRF-based single-vesicle imaging assay which delivered molecular beacon probes into exosomes and thus induced an amplified fluorescence of target miRNA (Fig. 5E,
). They performed a direct visualization of single vesicles and in-situ quantitative analysis of miR-21 in human serum samples and found that this assay showed better performance than conventional PCR assay in distinguishing cancer patients from healthy subjects [119].

Thermophoresis-assisted detection
Zhao et al. developed a thermophoretic sensor for in situ detection of exosomal miRNAs without the need of RNA extraction or target amplification (Fig. 5F). Aptamer modified in nanoflares could bind to target exosomal miRNA, inducing the appearance of fluorescence. The fluorescent signal became amplified after thermal electrophoretic accumulation, allowing the sensitive detection of 0.36 fM exosomal miRNA in a small volume of serum sample [175]. In addition, Han et al. proposed a DNA tetrahedron-based thermophoretic assay (DTTA) which achieved a detection limit of 14 aM mRNA in serum exosomes. After internalized by exosomes, the two fluorophore-labeled recognition sequences of DNA tetrahedron could bind to target mRNA, leading to an increase in FRET signal. Thermophoretic effect was applied to further amplify the FRET signal, which achieved a highly sensitive detection of PSA mRNA in exosomes. The DTTA assay showed that exosomal PSA mRNA performed better than serum PSA protein in discriminating prostate cancer from benign prostatic hyperplasia (AUC: 0.93 versus 0.74), providing a new approach for precise detection of prostate cancer [183].

CRISPR/Cas system-assisted detection
Recently, CRISPR/Cas system has offered new opportunities to develop analytical methods for the detection and quantification of nucleic acids in exosomes. The strategy of integrating nucleic acid amplification with CRISPR/Cas has been proposed to improve analytical specificity and sensitivity [184]. For instance, the platform of rolling circular amplification-assisted CRISPR/Cas9 cleavage (RACE) was conducted by Wang et al. to detect multiple exosomal miRNAs [176]. During RCA process, padlock probe recognized single base differences in the presence of HiFi Taq DNA ligase. The amplification product of long ssDNA, which consisted of a large number of repeated target sequences and PAM structures, was specifically recognized by Cas9 nuclease. Consequently, the TaqMan probe hybridized with ssDNA was completely cleaved by Cas9 protein, allowing “turn on” fluorescence change that could be conveniently measured by a spectroscopy. As a result, this RACE platform could be used for highly specific detection of single or multiple exosomal miRNAs from human plasma. However, the large number of naturally PAM structures in the genome may increase the risk of off-target effects, greatly impairing the specificity of analysis [185].

Machine learning
Machine learning refers to a technology that predicts and analyzes unknown data by building models of known data. As a crucial branch of artificial intelligence, machine learning has been widely used for the multiplex profiling of exosomal biomarkers. Algorithms such as linear discriminant analysis (LDA), principal component analysis (PCA), neural network (NN), support vector machine (SVM), and random forests (RF) have been developed to classify multivariable data into a typical classification model, which are then applied for the prediction and grouping of unknown biological data [186]. Kawakami et al. demonstrated that machine learning algorithms performed better than traditional logistic regression analysis to predict and diagnose epithelial ovarian cancer [187]. Wu et al. used the fluorescent signal of urine-derived exosomes as input data, and KNN (K-Nearest Neighbors) and SVM serving as machine learning models, were applied for exosomal biomarker analysis. By introducing machine learning algorithm, the diagnostic model could make an accurate diagnosis and classification of multiple diseases [188]. Liu et al. used LDA to determine a sum signature of seven exosomal biomarkers, which achieved a high accuracy in discriminating prostate cancer from benign disease [68]. Tian et al. analyzed a weighted sum of eight cancer-associated proteins of exosomes from 1 μL plasma via LDA [69]. PCA is an algorithm that transforms a group of probably-related variables into a series of linearly-unrelated variables through orthogonal transformation. Shin et al. used PCA to explore the features of cell exosomes and human plasma exosomes. As a result, the machine learning model could classify normal and lung cancer cell lines-derived exosomes with an accuracy of 95% and obtain an AUC of 0.912 in predicting lung cancer for the whole cohort [162]. Liu et al. employed RF, NN, and SVM to analyze multiple exosome-derived mRNAs of breast cancer patients, which exhibited improved diagnostic performance compared to a single marker [120]. These studies suggest the great potential of combining exosome
analysis and machine learning in cancer liquid biopsy. Notably, large data sets are required for typical machine learning approaches, while a limited number of clinical samples and insufficient data may lead to poor accuracy and reliability. The emergence of more powerful machine learning algorithms will favor the analysis of exosomes for liquid biopsy.

The implication of exosomes in cancer liquid biopsy
Recent studies have shown that exosomes are superior to CTCs and ctDNA in liquid biopsy for early diagnosis, disease monitoring, and prognosis prediction [34, 189, 190]. Herein, we summarized the application of exosomes in liquid biopsy for various cancers (Fig. 6, Table 4).

HCC
Hepatocellular cancer is the fourth cause of cancer-related death. Molecular signatures loaded into HCC-derived exosomes may be used to for diagnosis. Exosomal miR-21 was found to suppress the apoptosis of HCC cells and be upregulated in HCC patients [112]. Exosomal proteins such as CEA and GPC-3, were able to distinguish HCC patients from healthy subjects [193], which may serve as promising biomarkers for noninvasive cancer diagnosis. In a study containing 158 samples, plasma was collected for the detection of 10 HCC-specific genes, including alpha-fetoprotein (AFP), GPC3, albumin, apolipoprotein H, etc. [61]. It was observed that higher fluorescent signals were obtained in HCC cohort via ddPCR in comparison with noncancer cohorts. The 10 gene signatures were further computed by machine learning, which showed great potential to distinguish early-stage HCC from at-risk liver cirrhosis with an AUC of 0.93. Nakano et al. compared the expression levels of exosomal miR-92b and circulating AFP among HCC patients who received liver transplantation [194]. It was revealed that exosomal miR-92b could predict early recurrence of HCC with an AUC of 0.925, while the AUC of AFP was 0.651. Zhu et al. integrated plasma exosomal RNA-sequence, cell-free RNA-sequence and
TCGA tissue RNA-sequence datasets to identify 5 non-coding RNAs (circ-0073502, circ-0080695, SNORD3B-1, LINCO1226 and HULC) as potential biomarkers of liver cancer. In addition, a panel of SNORD3B-1, circ-0080695 and miR-122 showed the highest AUC (89.4%) to classify liver cancer patients from healthy donors in comparison with other marker panels. By the selected panel, 79.2% AFP-negative samples and 77.1% early-stage liver cancer samples were successfully detected in the testing and validation sets, which indicated the potential of exRNAs panel in the early diagnosis of liver cancer [210].

PDAC
As one of the most recognized indicators associated with pancreatic cancer progression, miRNA-10b is now being widely studied for the early diagnosis of pancreatic ductal adenocarcinoma (PDAC) [211]. Joshi et al. indicated that the levels of exosomal miR-10b were remarkably different among pancreatic cancer patients, at-risk patients with chronic pancreatitis (CP) and healthy individuals, which suggested the potential of miR-10b in diagnosing pancreatic cancer and predicting CP patients who may develop to PDAC [173]. The same conclusion was obtained by Pang’s group by using a dual-SERS biosensor for one-step detection of mRNAs in exosomes [195]. Melo et al. found that GPC-1+ circulating exosomes (GPC-1+ crExos) exhibited high specificity and sensitivity to identify PDAC patients from healthy individuals and chronic pancreatitis (CP) and healthy individuals, which suggested the potential of miR-10b in diagnosing pancreatic cancer and predicting CP patients who may develop to PDAC [173]. The same conclusion was obtained by Pang’s group by using a dual-SERS biosensor for one-step detection of mRNAs in exosomes [195]. Melo et al. found that GPC-1+ circulating exosomes (GPC-1+ crExos) exhibited high specificity and sensitivity to identify PDAC patients from healthy individuals and chronic pancreatitis (AUC = 1.0), which was superior to CA199 (AUC = 0.739). Moreover, the levels of GPC-1+ crExos were correlated with tumor burden and survival in patients before and after surgery, suggesting the potential of GPC-1 serving as a reliable biomarker for treatment effect and prognostic monitoring [38]. In addition, the combination of GPC-1 and CD63 was demonstrated to show 99% sensitivity and 82% specificity in distinguishing PDAC patients from healthy subjects [197]. Furthermore, migration inhibitory factor (MIF) was reported to have better performance than GPC-1 and EGFR in the discrimination of different stages of pancreatic cancer [199].

NSCLC
Non-small cell lung cancer accounts for over 80% of lung cancer-induced deaths [1]. High level of PD-L1 was detected in serum exosomes of NSCLC patients compared to normal individuals [132]. The diagnostic value of exosomal PD-L1 was further confirmed by Pang et al. in a larger cohort of patients with an AUC of 0.97 [90]. Ma et al. found that the expression of exosomal miR-21 was higher in patients with recurrent NSCLC compared with healthy individuals [201]. However, high levels of exosomal miR-21 were also identified in other cancers such as colorectal cancer, breast cancer, and liver cancer [123, 189, 204]. Therefore, the detection of multiple miRNAs may be more valuable for NSCLC diagnosis. Wu et al. demonstrated that miR-21, miR-378, miR-139, and miR-200 were differentially expressed between NSCLC patients and healthy donors, providing more optional biomarkers for the early diagnosis of NSCLC [123]. Notably, the experimental results showed that more amounts of exosomal RNAs were obtained in urine-derived exosomes of NSCLC patients than that from plasma and bronchoalveolar lavage fluid, which may provide a new direction of sample selection to analyze exosomes [62].

Breast cancer
Breast cancer (BC) is the most common cause of cancer-related death among females. Early diagnosis can effectively suppress the mortality and achieve better treatment outcomes. Despite as a widely used biomarker, CA15-3 (carbohydrate antigen 15-3) is not sensitive enough to diagnose primary and metastatic breast cancer (MBC) [203]. Lee et al. demonstrated that cancer cell-derived exosomal miR-21, miR-222, and miR-200c could be quantified in body fluids and used for breast cancer diagnosis [204]. Lu et al. reported that the combination of RDW (red blood cell distribution width), MPV (mean platelet volume), and CA15-3 showed better specificity and sensitivity to identify breast cancer than single biomarker [203]. In addition, an exosome signature was identified by computing weighted sum of eight biomarkers (CA15-3,
Table 4 Exosomes as biomarkers for cancer liquid biopsy

| Cancer types | Exosome sources | Sample volume | Exosomal biomarker | Clinical samples | Diagnostic performance | Clinical significance | Ref. |
|--------------|----------------|---------------|--------------------|-------------------|------------------------|----------------------|------|
| Gastric Cancer | Serum | Inc HOTTIP | 126 GC patients; 120 healthy donors | AUC = 0.827 | Early diagnosis | [191] |
|              | Serum | miR-15b-3p | 108 GC patients; 108 healthy donors | AUC of 0.820; specificity of 80.6%; sensitivity of 74.1% | Early diagnosis | [192] |
| HCC | Plasma | 100 μL | AFP; GPC3; ALB; APOH; FABP1; FGB; FG; AHSG; RBM4; TF mRNA | 36 HCC patients; 26 Cirrhosis | AUC of 0.87; sensitivity of 93.8%; specificity of 74.5% | Early diagnosis | [61] |
|              | Serum | miRNA-21; IncRNA-A TB | 72 HCC patients | Higher in HCC patients | Prognostic significance | Early diagnosis | [189] |
| HCC | Serum | miR-92b | 28 non-HCC; 28 HCC patients without recurrence; 43 HCC patients with early recurrence | Sensitivity of 85.7%; specificity of 86.0%; AUC = 0.925 | Early recurrence diagnosis after LDLT | [194] |
| PDAC | Plasma | 500 μL | miRNA-10b | 3 PDAC Patients; 3 CP Patients; 3 healthy donors | Higher in PDAC patients | Early diagnosis and progression monitoring | [173] |
|              | Plasma | miRNA-10b | PDAC patients; CP patients and healthy donors | Higher in PDAC patients | Early diagnosis | [195] |
|              | Mouse plasma samples | miR-3970-5p | 9 healthy donors; 9 PanIN patients; 9 PDAC patients | Accuracy of 65% | Early diagnosis | [196] |
| PDAC | Serum | Glypican1 | 192 patients; 100 healthy donors | Sensitivity of 100%; specificity of 100%; positive predictive value of 100%; negative predictive value of 100%; AUC of 1.0 | Early diagnosis | [38] |
| Plasma | 25 μL | Glypican1 | 20 PDAC patients; 7 benign pancreatic disease; 11 healthy donors | 99% sensitivity and 82% specificity | Stage classification | [197] |
| Serum | 5 μL | EpCAM, Glypican1 | | 90% accuracy for pancreatic cancer or normal pancreatic epithelial cell lines; 87 and 90% predictive accuracy for HC and EPC individual samples | Early diagnosis | [198] |
| Serum | 2 μL | MIF | 4 patients at stage 1 ~ 2; 37 patients at stage 3 | Discriminatory sensitivity of 95.7% | Stage classification | [199] |
| CRC | Serum | hsa-circ-0004771 | 179 patients; 45 healthy donors | AUC of 0.86, 0.88 to differentiate stage VII CRC patients and CRC patients from HCs | Early diagnosis | [200] |
| Plasma | 25 μL | Epcam-CD63 | 59 cancer patients; 20 healthy donors | AUC of 0.96 | Early diagnosis; prognosis prediction | [125] |
Table 4 (continued)

| Cancer types | Exosome sources | Sample volume | Exosomal biomarker | Clinical samples | Diagnostic performance | Clinical significance | Ref. |
|--------------|----------------|---------------|-------------------|------------------|-----------------------|----------------------|------|
| NSCLC        | Plasma         | 1 mL          | miRNA-21          | NSCLC patients; recurrence of NSCLC patients; healthy individuals | Higher in NSCLC patients | Early diagnosis and drug resistance in advanced cancers | [201] |
|              | Serum          | 50 μL         | PD-L1             | 5 patients; 4 healthy donors | Higher in NSCLC patients | Early diagnosis | [132] |
|              | Serum          | 4 μL          | PD-L1             | 7 patients at stage 1–2, 10 patients at stage 3–4, 12 healthy controls | AUC of 0.97 | Early diagnosis | [90] |
| Breast Cancer| Plasma         | 1 mL          | EpCAM             | 6 BC patients; 3 healthy donors | Higher in BC patients | Early diagnosis | [71] |
|              | Plasma         | 1.5 mL        | CD63; EGFR; EpCAM | 4 patients; 4 treated patients; 4 healthy donors | Higher in NSCLC patients | Early diagnosis and therapeutic effect evaluation | [159] |
|              | Serum          | 50 μL         | PD-L1             | 5 patients; 4 healthy donors | Higher in NSCLC patients | Early diagnosis | [132] |
|              | Serum          | 4 μL          | PD-L1             | 7 patients at stage 1–2, 10 patients at stage 3–4, 12 healthy controls | AUC of 0.97 | Early diagnosis | [90] |
| Blood        | Serum          | 3.6 μL        | EpCAM             | 20 BC patients; 10 healthy donors | AUC of 1; AUC of 1 | Early diagnosis | [134] |
|              | Serum          | 50 μL         | PD-L1             | 7 patients with metastatic; 8 patients without metastatic; 6 healthy donors | Higher in BC patients | Prognosis prediction and progression monitoring | [114] |
|              | Serum          | 3.6 μL        | EpCAM             | 20 BC patients; 10 healthy donors | AUC of 1; AUC of 1 | Early diagnosis | [134] |
|              | Serum          | 3.6 μL        | PD-L1             | 7 patients with metastatic; 8 patients without metastatic; 6 healthy donors | Higher in BC patients | Prognosis prediction and progression monitoring | [114] |
|              | Blood          | CA153         | 104 BC patients; 100 breast hyperplasia patients and 100 healthy controls | Higher in BC patients | Differential diagnosis | [203] |
|              | Serum          | miR-21, miR-222, miR-200c | Luminal, HER2+, and TN breast cancer patients | Higher in BC patients | Classification of molecular subtypes of breast cancer | [204] |
|              | Plasma         | 1 μL          | CA153; EpCAM      | 36 MBC patients before salvage treatment; 21 NMBC patients before surgical therapy; 66 age-matched healthy donors | AUPRC of 0.9826 | Differential diagnosis of BC and healthy donors | [69] |
|              | Plasma         | 1 μL          | CA153; CA125; CEA; HER2; EGFR; PSMA; EpCAM; VEG | 36 MBC patients before salvage treatment; 21 NMBC patients before surgical therapy; 66 age-matched healthy donors | AUPRC of 0.9826 | Differential diagnosis of BC and healthy donors | [69] |
|              | Plasma         | 1 μL          | CA153; CA125; CEA; HER2; EGFR; PSMA; EpCAM; VEG | 36 MBC patients before salvage treatment; 21 NMBC patients before surgical therapy; 66 age-matched healthy donors | AUPRC of 0.8672 | Differential diagnosis of MBC and NMBC | [69] |
|              | Plasma         | 1 μL          | CA153; CA125; CEA; HER2; EGFR; PSMA; EpCAM; VEG | 36 MBC patients before salvage treatment; 21 NMBC patients before surgical therapy; 66 age-matched healthy donors | AUPRC of 0.8672 | Differential diagnosis of MBC and NMBC | [69] |
|              | Plasma samples | EpCAM         | Various breast cancer patients and healthy individuals | Higher in BC patients | Early diagnosis | [115] |
| Cancer types  | Exosome sources | Sample volume | Exosomal biomarker | Clinical samples | Diagnostic performance | Clinical significance | Ref. |
|--------------|-----------------|---------------|-------------------|------------------|-----------------------|----------------------|------|
| Prostate Cancer | Urine           | 50-150 mL     | miR-196a; miR-143-3p; miR-196-5p; miR-501-3p; | 28 PCA patients; 19 healthy donors | AUC miR-196a = 0.92  
AUC miR143-3p = 0.72  
AUC miR196-5p = 0.73  
AUC miR501-3p = 0.69 | Early diagnosis | [205] |
| Plasma       | 750 μL          | miR-217; miR-23b-3p | 10 patients; 10 healthy donors | Higher in PCA patients | AUC miR217 = 0.72  
AUC miR23b-3p = 0.73 | Early diagnosis | [206] |
| Serum        | 400 μL          | EphrinA2      | 50 PCA patients; 21 BPH patients; 20 healthy donors | AUC of 0.7666 | AUC miR217 = 0.72  
AUC miR23b-3p = 0.73 | Early diagnosis; distinguish PCA from BPH patients | [207] |
| Serum        | 25 μL           | EpCAM and PSMA | 10 PCA patients; 5 healthy donors | Higher in PCA patients | AUC miR217 = 0.72  
AUC miR23b-3p = 0.73 | Early diagnosis | [127] |
| Ovarian Cancer | Ascites         | 2 mL          | TUBB3 mRNA | 52 mCRPC patients | Higher in PCA patients | Prognosis | [208] |
| Plasma       | 20 μL           | CA125; EpCAM; CD24 | 20 patients; 10 healthy donors | Higher in OCA patients | AUC CA125 = 1.0  
AUC EpCAM = 1.0  
AUC CD24 = 0.91 | Early diagnosis | [116] |
| Plasma       | 200 μL          | CD24; EpCAM; FRα | 20 OVCA patients; 10 non-cancer controls | AUC CD24 = 1.0  
AUC EpCAM = 1.0  
AUC FRα = 0.995 | Early diagnosis | [165] |
| Plasma       | 200 μL          | miR-4732-5p   | 21 healthy controls and 34 epithelial ovarian cancer patients | AUC miR4732-5p = 0.889 | Early diagnosis | [209] |

ALB Albumin, APOH Apolipoprotein H, AUPRC Area under the Precision-Recall Curves, FABP1 Fatty acid binding protein 1, FGB Fibrinogen beta chain, FGG Fibrinogen gamma chain, AHSG Alpha 2-HS glycoprotein, RBP4 Retinol binding protein 4, TF Transferrin, LDLT Living donor liver transplantation, CP Chronic pancreatitis, PanIN Pancreatic intraepithelial neoplasia, MIF Migration inhibitory factor
CA125, CEA, HER2, EGFR, PSMA, EpCAM, and VEGF) through machine learning. Consequently, the signature showed a high discriminative accuracy to differentiate MBC from non-metastatic ones and age-matched healthy donors (91.1%). Moreover, the exosome signature was reported to accurately monitor MBC treatment response and serve as an independent prognostic factor for progression-free survival in MBC patients.

Prostate cancer
PSA is a widely used biomarker for the detection of prostate cancer. However, increased PSA was also identified in inflammatory diseases such as benign prostatic hyperplasia (BPH) [213]. Therefore, the development of sensitive and specific biomarker is urgently needed to diagnose patients at early stage and monitor the progression of cancer. Li et al. reported that exosomal ephrinA2 had superior capability to blood circulating PSA to differentiate prostate cancer patients from BPH patients with an AUC of 0.906 [207]. Moreover, increased EpCAM and PSMA were found in the serum exosomes of prostate cancer [127]. In addition, the expression of exosomal TUBB3 mRNA was reported to be associated with poor progression-free survival of abiraterone in metastatic castration-resistant prostate cancer patients [208].

Exosomes in clinical trial and use for cancer liquid biopsy
Due to the priority of living-cell secretion, large amounts and stable circulation compared to CTC and ctDNA, exosome-based liquid biopsy has been tested in clinical trials and several of them have been approved and reached the market. In 2016, Exosome Diagnostics proposed the first exosome-based liquid biopsy in the world, ExoDx™ Lung (ALK), for the isolation and analysis of exosomal RNA from blood samples. At CLIA-certified laboratory, ExoDx™ Lung (ALK) was proved to be an accurate, real-time tool to detect EML4-ALK mutations in NSCLC patients with 88% sensitivity and 100% specificity, which provides a more direct and sensitive method to detect gene fusions than cfDNA. In addition, the ExoDx Prostate IntelliScore (EPI) has been certified by FDA. Based on the detection of ERG, PCA3, and SPDEF RNA in exosomes, EPI provides a risk score to predict whether a patient with PSA from 2 to 10 ng/mL is likely to develop higher-grade prostate cancer [214]. According to ExoDx, 93% of sensitivity was achieved in prospective studies, and 26% of unnecessary needle biopsies were avoided when the EPI threshold was set at 15.6 [215]. Three independent, prospective, and multicenter clinical trials declared that EPI outperformed standard of care and could be used to assist in the early diagnosis of prostate cancer and eliminate unnecessary prostate biopsy [64]. Moreover, MedOncAlyzer 170 is a newly developed liquid biopsy system capable of detecting both exosomal RNA and ctDNA in a single trial. It can identify significant and functional mutations in multiple cancer types from small volumes (0.5 ml) of patient blood or plasma. Due to the unique formation manner of exosome and ctDNA, MedOncAlyzer 170 is accurate and highly sensitive to detect mutation at all stages of cancer progression and treatment. Although the clinical application value has been verified, larger clinical samples, populations and trials are still needed to confirm the role of exosome-based liquid biopsy in cancer diagnosis and treatment.

Conclusions and perspectives
At present, the limitation of tissue biopsy has been gradually recognized in the field of precision medicine. On the contrary, liquid biopsy has the advantages of minimal invasiveness, easy sample acquisition, and dynamic analysis. Exosomes have been confirmed to stably circulate in body fluids and contain diverse information that reflects the status of tumor progression [28, 33]. The potential of exosome serving as diagnostic and prognostic biomarkers has been investigated in a variety of cancers. However, the high heterogeneity and nano-size of exosomes have posed great technical challenges to the acquisition of their molecular information and interactions. In this review, we have summarized the advantages and drawbacks of conventional and novel techniques to isolate, characterize and detect exosomes. Techniques based on physical or biological characteristics are being widely developed for exosome separation, and the application of microfluidic devices holds great potential for the ultrafast separation of pure exosomes with high yields. Although revolutionary progress has been achieved, there is no standardized method for the high-throughput, high-purity, and minimal damage separation of exosomes from both cell culture medium and human body fluids. Diverse molecules contained in the circulating exosomes have highlighted the potential of exosomes in liquid biopsy. Faster and more convenient methods are required to validate the exosomal cargoes as biomarkers in the diagnosis of cancer. Most new detection platforms, although superior to conventional methods, still face the challenge of low sensitivity and high heterogeneity of different exosome subsets. The technology of single exosome detection and analysis may reveal the unique molecular profile of specific exosomes and provide a plausible strategy to obtain accurate cancer-related information. The further exploration in exosome heterogeneity will address many of the challenges in current exosome studies. Improvements in developing new strategies to isolate exosomes from body fluids and profile exosomal contents in a fast and sensitive way will facilitate the practical application of exosome-based liquid biopsy for cancer precision medicine.
Acknowledgements
We thank the members of the Zhang laboratory for helpful discussion and paper preparation.

Authors’ contributions
YD, LYX, WMV, and GJM conducted literature collection and article writing. YD, LYX, and WMV drew the figures and tables. CH, XWR, FXJ, and ZX conducted paper revision. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (81972310), Distinguished Young Scholar Project of Jiangsu Province (BK20200043), Major Natural Science Research Project for Universities in Jiangsu Province (18KJA320001), Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province (2019GSZDSYS01, 2019GSZDSYS02), Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, China.
2. Department of Clinical Laboratory Medicine, Nantong Tumor Hospital, Nantong 226361, Jiangsu, China.
3. Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province, Gansu Hospital of Jiangsu University, Lanzhou 730000, Gansu, China.
4. Department of Oncology, Lianyungang Hospital Affiliated to Jiangsu University, Lianyungang 222000, Jiangsu, China.

Received: 4 November 2021 Accepted: 15 January 2022
Published online: 18 February 2022

References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
2. Li S, Yi M, Dong B, Tan X, Luo S, Wu K. The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. Int J Cancer. 2021;148(11):2640–51.
3. Sala M, Ros M, Saltel F. A complex and evolutative character: two face aspects of ECM in tumor progression. Front Oncol. 2020;10:1620.
4. Kalluri R, LeBleu VS. The biology function and biomedical applications of extracellular vesicles. New York: Science; 2020. p. 367.
5. Caby M-P, Lankar D, Vincendeau-Schemer C, Raposo G, Bonnerot C. Exosomal sorting during melanogenesis. Dev Cell. 2011;21:708–21.
6. Street JM, Barran PE, Mackay CL, Weidt S, Balmforth C, Walsh TS, et al. Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J Transl Med. 2012;10:5.
7. Shao H, Im H, Castro CM, Brakefield X, Weissleder R, Lee H. New techniques for analysis of extracellular vesicles. Chem Rev. 2018;118:1917–50.
8. Lin S, Yu Z, Chen D, Wang Z, Miao J, Li Q, et al. Progress in microfluidics-based exosome separation and detection technologies for diagnostic applications. Small (Weinheim an der Bergstrasse, Germany). 2020;16:e1903916.
9. Zhang Y-C, Zhou Q, Wu Y-L. The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer. J Hematol Oncol. 2017;10:167.
10. Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016;30:836–48.
11. Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Tasic Mark M, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527:329–35.
12. Kawamura S, Inrama H, Wada K, Takashashi K, Minezaki S, Kainuma M, et al. Exosome-encapsulated microRNA-4525, microRNA-451a and microRNA-21 in portal vein blood is a high-sensitive liquid biomarker for the selection of high-risk pancreatic ductal adenocarcinoma patients. J Hepatobiliary Pancreat Sci. 2019;26:663–72.
13. Nam M, Ma Y, Jeffreys SA, Oppermann T, Young F, Khan T, et al. Detection of AR-V7 in liquid biopsies of castrate resistant prostate cancer patients: a comparison of AR-V7 analysis in circulating tumor cells, circulating tumor RNA and exosomes. Cells. 2019;8(7):688.
14. Cai X, Janku F, Zhan Q, Fan J-B. Accessing genetic information with liquid biopsy. Trends Genet. 2015;31:564–75.
15. Ye Q, Ling S, Zheng X, Xu K. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019;18:114.
16. Vaidyanathan R, Soon RH, Zhang P, Jiang K, Lim CT. Cancer diagnosis: from tumor to liquid biopsy and beyond. Lab Chip. 2018;19:11–34.
17. Wu W, Hurley J, Roberts D, Chakrabortty S, Endler D, Noerholm M, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021;32(4):466–77.
18. Li P, Kaslan M, Lee SH, Yao J, Gao Z. Progress in exosome isolation techniques. Theranostics. 2017;7:789–804.
19. He C, Zheng S, Luo Y, Wang B. Exosome theranostics: biology and translational medicine. Theranostics. 2018;8:237–55.
20. Kanwar SS, Dunlay CJ, Simeone DM, Naigrath S. Microfluidic device (ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes. Lab Chip. 2014;14:1891–900.
21. Dobhal G, Datta A, Ayapova D, Teesdale-Spittle P, Gotemrah RV. Isolation, characterisation and detection of breath-derived extracellular vesicles. Sci Rep. 2020;10:17381.
22. Patel GK, Khan MA, Zubair H, Srivastava SK, Khushman M, Singh S, et al. Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. Sci Rep. 2019;9:5335.
23. An M, Wu J, Zhu J, Lubman DM. Comparison of an optimized ultracentrifugation method versus size-exclusion chromatography for isolation of exosomes from human serum. J Proteome Res. 2018;17:3599–605.
24. Lobb RJ, Becker M, Wen SW, Wong CSF, Wiegmans AP, Leimgruber A, et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracellular Vesicles. 2015;4:20731.
25. Wang W, Luo J, Wang S. Recent progress in isolation and detection of extracellular vesicles for cancer diagnostics. Adv Healthc Mater. 2018;7:e1800484.
26. Hu T, Wolfram J, Srivastava S. Extracellular vesicles in cancer detection: hopes and hype. Trends Cancer. 2021;7(2):122–33.
27. Shao H, Chung J, Issadore D. Diagnostic technologies for circulating tumour cells and exosomes. Biosci Rep. 2015;36:e00292.
28. Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W. Exosomes in cancer: small particle, big player. J Hematol Oncol. 2015;8:83.
29. Hu W, Liu C, Bi Z-Y, Zhou Q, Zhang H, Li L-L, et al. Comprehensive landscape of extracellular vesicle-derived RNAs in cancer initiation, progression, metastasis and cancer immunity. Mol Cancer. 2020;19:102.
30. Wollert T, Hurley JH. Molecular mechanism of multivesicular body biogenesis by ESCRT complexes. Nature. 2010;464:864–9.
31. Vietri M, Radulovic M, Stenmark H. The many functions of ESCRTs. Nat Rev Mol Cell Biol. 2020;21:25–42.
32. van Niel G, Chin-Foong S, Ramos M, Mohsin L, Saag P, et al. The tetratricopeptide CD63 regulates ESCRT-independent and -dependent endosomal sorting during melanogenesis. Dev Cell. 2011;21:708–21.
33. van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213–28.
34. Li W, Li C, Zhou T, Liu X, Liu X, Li X, et al. Role of exosomal proteins in cancer diagnosis. Mol Cancer. 2017;16:145.
35. Hoshino A, Kim HS, Bojmar L, Gyan KE, Cioffi M, Hernandez J, et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell. 2020;182(4):1044–1061 e118.
36. He M, Crow J, Roth M, Zeng Y, Godwin AK. Integrated immunosolation and protein analysis of circulating exosomes using microfluidic technology. Lab Chip. 2014;14:3773–80.
37. Jakobsen KR, Paulsen BS, Bæk R, Varming K, Sorensen BS, Jørgensen MM. Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma. J Extracellular Vesicles. 2015;4:26659.
38. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glycan-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523:177–82.
39. Skog J, Würdinger T, van Rijn S, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470–8.
40. Zhou L, Wang W, Wang F, Yang S, Hu J, Lu B, et al. Plasma-derived extracellular miR-15a-5p as a promising diagnostic biomarker for early detection of endometrial carcinoma. Mol Cancer. 2021;20:57.
41. Fang T, Lv H, Lv G, Li T, Wang C, Han Q, et al. Tumor-derived extracellular miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of prostate cancer. J Extracellular Vesicles. 2018;7:18911.
42. Barile L, Vassalli G. Exosomes: therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017;174:63–78.
43. Royo F, Théry C, Falcón-Pérez JM, Nieuwland R, Wittwer KW. Methods for separation and characterization of extracellular vesicles: results of a worldwide survey performed by the ISEV rigor and standardization subcommittee. Cells. 2020;9(9):1955.
44. Johnstone RM, Adam M, Hammond JR, Orr L, Turcotte C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262:9412–20.
45. Vidal M, Mangeat P, Hoekstra D. Aggregation reroutes molecules from a recycling to a vesicle-mediated secretion pathway during reticulocyte maturation. J Cell Sci. 1997;110(Pt 16):1867–77.
46. Poliakov A, Spilmann M, Dokland T, Amling CL, Mobley JA. Structural heterogeneity and protein composition of exosome-like vesicles (prostasomes) in human semen. Prostate. 2009;69:159–67.
47. Taylor DD, Shah S. Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes. Methods (San Diego, Calif). 2015;73:1–10.
48. Haraszt RA, Miller R, Stoppato M, Sere YY, Coles A, Didiot M-C, et al. Exosomes produced from 3D cultures of MCFs by tangential flow filtration show higher yield and improved activity. Mol Ther. 2018;26:2238–47.
49. Alvarez ML, Khosroheidari M, Kanchi Ravi R, DiStefano JK. Comparing of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney Int. 2012;82:1024–32.
50. Boing AN, van der Pol E, Grootemaat AE, Coumans FAW, Sturk A, Nieuwland R. Single-step isolation of extracellular vesicles by size-exclusion chromatography. J Extracellular Vesicles. 2014;3.
51. Guo J, Wu C, Lin X, Zhou J, Zhang J, Zheng W, et al. Establishment of a simplified dichotomic size-exclusion chromatography for isolating extracellular vesicles toward clinical applications. J Extracellular Vesicles. 2021;10:e12145.
52. Monguïo-Tortajada M, Gálvez-Montón C, Bayes-Genis A, Roura S, Borrás FE. Extracellular vesicle isolation methods: rising impact of size-exclusion chromatography. Cell Mol Life Sci. 2019;76:2369–82.
53. Wei R, Zhao L, Kong G, Liu X, Zhu S, Zhang S, et al. Combination of size-exclusion chromatography and ultracentrifugation improves the proteomic profiling of plasma-derived small extracellular vesicles. Biocl Proc Onlin. 2020;22:12.
54. Weng Y, Suiz S, Shin H, Yang Y, Chen Y, Zhang L, et al. Effective isolation of exosomes with polyethylene glycol from cell culture supernatant for in-depth proteome profiling. Sci Rep. 2016;14:6460–6.
55. Rieder MA, Hurwitz SN, Megck DS. ExtraPEG: a polyethylene glycol-based method for enrichment of extracellular vesicles. Sci Rep. 2016;6:23978.
78. Hattori Y, Shimada T, Yasui T, Kaji N, Baba Y. Micro- and nanopillar chips for continuous separation of extracellular vesicles. Anal Chem. 2019;91:6514–21.
79. Dong L, Zieren RC, Horie K, Kim C-J, Mallick E, Jing Y, et al. Comprehensive evaluation of methods for small extracellular vesicles separation from human plasma, urine and cell culture medium. J Extracellular Vesicles. 2020;10:e12044.
80. Wan Y, Cheng G, Liu X, Hao S-J, Nisic M, Zhu C-D, et al. Rapid magnetic isolation of extracellular vesicles via lipid-based nanoprobes. Nat Biomed Eng. 2017;1:10058.
81. Lee K, Shao H, Weissleder R, Lee H. Acoustic purification of extracellular microvesicles. ACS Nano. 2015;9:2321–7.
82. Kang Y-T, Hadlock T, Sajja R, Nagrath S. Exosome purification. J Extracellular Vesicles. 2020;10:e12044.
83. Luo Y, Yu X, Chen X, Chen H, Zhang L, Hu X. Method for detection and enrichment of extracellular vesicles. (CN202110641317.4)
84. Li B, Pan W, Liu C, Guo J, Shen J, Feng L, et al. Homogenous magnetofluorescent nanosensor for tumor-derived exosome isolation and analysis. ACS Sensors. 2020;5:2052–60.
85. Rho J, Chung J, Lim H, Lionic M, Shao H, Castro MM, et al. Magnetic nanosensor for detection and profiling of erythrocyte-derived microvesicles. ACS Nano. 2015;9:11227–33.
86. Chen Y, Pan W, Cheng L, Wang Y, Liu M, Yang Q, et al. Exosome detection via the ultrafast-isolation system: EXODUS. Nat Methods. 2021;18:122–8.
87. Wan Y, Maurer M, He H-Z, Xiao Y-Q, Hao S-J, Zhang W-L, et al. Enrichment of extracellular vesicles with lipid nanoprobe functionalized nanostructured silica. Lab Chip. 2019;19:2346–53.
88. Kang Y-T, Puncell E, Palacios-Roldon C, Lo T-W, Ramnath N, Jolly S, et al. Isolation and profiling of circulating tumor-associated exosomes using extracellular vesicular lipid-protein binding affinity based microfluidic device. Small (Weinheim an der Bergstrasse, Germany). 2019;15:e1903600.
89. Nakai W, Yoshida T, Dez D, Miyatake Y, Nishiyama T, Imawaka N, et al. A novel affinity-based method for the isolation of highly purified extracellular vesicles. Sci Rep. 2016;6:33935.
90. Pang Y, Shi J, Yang X, Wang C, Sun Z, Xiao R. Personalized detection of circulating exosomal PD-L1 based on FeO@TiO2 isolation and SERS immunoassay. Biosens Bioelectron. 2020;148:111800.
91. Ku A, Lim HC, Evander M, Lilja H, Laurell T, Scheding S, et al. Acoustic enrichment of extracellular vesicles from biological fluids. Anal Chem. 2018;90:8011–9.
92. Wu M, Quyang Y, Wang Z, Zhang R, Huang P-H, Chen C, et al. Isolation of exosomes from whole blood by integrating acoustic and microfluidics. Proc Natl Acad Sci U S A. 2017;114:10584–9.
93. Gu Y, Chen C, Mao Z, Bachman H, Becker R, Rufo J, et al. Acoustofluidic centrifuge for nanoparticle enrichment and separation. Sci Adv. 2021;7(1):eabc0467.
94. Gardiner C, Dio D, Sahoo S, Théry C, Witwer KW, Wauben M, et al. Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey. J Extracellular Vesicles. 2015;6:32945.
95. Théry C, Witwer KW, Akawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracellular Vesicles. 2018;7:1535750.
96. Sharma S, Rasool HI, Palanisamy V, Mathisen C, Schmidt M, Wong DT, et al. Structural-mechanical characterization of nanoparticle exosomes in human saliva, using correlative AFM, FSEM, and force spectroscopy. ACS Nano. 2010;4:1921–6.
97. Tian Y, Ma L, Gong M, Su G, Zhu S, Zhang W, et al. Protein profiling and sizing of extracellular vesicles from colorectal cancer patients via flow cytometry. ACS Nano. 2018;12:671–80.
98. Sharma S, Gillespie BM, Palanisamy V, Ginzewski JK. Quantitative nanostructural and single-molecule force spectroscopy biomolecular analysis of human-saliva-derived exosomes. Langmuir. 2011;27:14394–400.
99. Li B, Liu C, Pan W, Shen J, Guo J, Luo T, et al. Facile fluorescent aptasensor using aggregation-induced emission luminescence for exosomal proteins profiling towards liquid biopsy. Biosens Bioelectron. 2020;168:115250.
100. Street JM, Koritzinsky BH, Gilspie DM, Star RA, Yuen PST. Urine exosomes: an emerging trove of biomarkers. Adv Clin Chem. 2017;78:103–22.
101. Carnino JM, Lee H, Jin Y. Isolation and characterization of extracellular vesicles from Broncho-alveolar lavage fluid: a review and comparison of different methods. Respir Res. 2019;20:240.
102. Kurian TK, Banik S, Gopal D, Chakrabarti S, Mazumder N, Elucidating methods for isolation and quantification of exosomes: a review. Mol Biotechnol. 2021;63:249–66.
103. Božič D, Sitar S, Junka I, Šukelj R, Pajnič M, Zagar E, et al. Viscosity of plasma as a key factor in assessment of extracellular vesicles by light scattering. Cells. 2019;8(9):1046.
104. Bachurski D, Schuldner M, Nguyen P-H, Malz A, Reiners KS, Grenz PC, et al. Extracellular vesicle measurements with nanoparticle tracking analysis - An accuracy and repeatability comparison between NanoSight NS300 and ZetaView. J Extracellular Vesicles. 2019;8:1536016.
105. Coumans FAW, van der Pol E, Böing AN, Haji N, Sturk G, van Leeuwen TG, et al. Reproducible extracellular vesicle size and concentration determination with tunable reversible pulse sensing. J Extracellular Vesicles. 2014;3:2922.
106. Jeppesen DK, Fenix AM, Franklin JF, Higginbotham JN, Zhang Q, Zimmerman LJ, et al. Reassessment of exosome composition. Cell. 2019;177(2):428–445 e18.
107. Ueda K, Ishikawa N, Tatematsu S, Aichikawa A, Saii N, Fuji H, Nakagawa H. Antibody-based coupled monolithic silica microtub for hgh throughput molecular profiling of circulating exosomes. Sci Rep. 2014;4:6232.
108. Yokoyama S, Takeuchi A, Yamaguchi S, Mitani Y, Watanabe T, Matsuda K, et al. Clinical implications of carcinoembryonic antigen detection in serum exosomal fraction-measurement by ELISA. PLoS One. 2017;12:e0183337.
109. Xia Y, Liu M, Yang Z, Yang Z, He W, Chen M, et al. A visible and colorimetric aptasensor based on DNA-capped single-wall carbon nanotubes for detection of exosomes. Biosens Bioelectron. 2017;92:8–15.
110. Chen Z, Cheng S-B, Cao P, Qiu Q-F, Chen Y, Xie M, et al. Detection of exosomes by ZnO nanowires coated three-dimensional scaffold chip device. Biosens Bioelectron. 2018;122:211–6.
111. Liang L, Kong M, Sheng Y, Wang S. An integrated detection method and detection chip for the separation, enrichment and detection of urine exosomes. (CN2016103868725)
112. Di H, Mi Z, Sun Y, Liu X, Liu X, Li A, et al. Nanoyze-assisted sensitive profiling of exosomal proteins for rapid cancer diagnosis. Theranostics. 2020;10:9303–14.
113. Jin D, Yang F, Zhang Y, Liu L, Zhou Y, Wang F, et al. ExoAPP: exosome-oriented, aptamer nanoprobe-enabled surface proteins profiling and detection. Anal Chem. 2018;90:14402–11.
114. Cao Y, Wang Y, Yu X, Jiang X, Li G, Zhao J. Identification of programmed death ligand-1 positive exosomes in breast cancer based on DNA amplification-responsive metal-organic frameworks. Biosens Bioelectron. 2020;166:112452.
115. Kashefi-Kheyrabadi L, Kim J, Chakravarty S, Park S, Gwak H, Kim SJ, et al. Detectable microfluidic device implemented with electrochemical aptasensor (DeMEAA) for sequential analysis of cancerous exosomes. Biosens Bioelectron. 2020;169:112622.
116. Im H, Shao H, Park YJ, Peterson VM, Castro MM, Weissleder R, et al. Label-free detection and molecular profiling of exosomes with a nanoplasmonic sensor. Nat Biotechnol. 2014;32:490–5.
117. Dong S, Wang Y, Liu Z, Zhang W, Yi K, Zhang X, et al. Beehive-inspired macroporous SERS probe for cancer detection through capturing and analyzing exosomes in plasma. ACS Appl Mater Interfaces. 2020;12:5136–46.
118. Wang H, Jiang D, Li W, Xiang Z, Zhao J, Yu B, et al. Evaluation of serum extracellular vesicles as noninvasive diagnostic markers of glioma. Theranostics. 2019;9:5347–58.
119. He D, Wang H, Ho S-L, Chan H-N, Hai L, He X, et al. Total internal reflection-based single-vesicle in situ quantitative and stoichiometric analysis of tumor-derived exosomal microRNAs for diagnosis and treatment monitoring. Theranostics. 2019;9:4494–507.
120. Liu C, Li B, Lin H, Yang G, Guo J, Cui B, et al. Multiplexed analysis of small extracellular vesicle-derived mRNAs by droplet digital PCR and machine learning improves breast cancer diagnosis. Biosens Bioelectron. 2021;194:113615.
121. Lee JH, Kim JA, Jeong S, Rhee WJ. Simultaneous and multiplexed detection of exosome microRNAs using molecular beacons. Biosens Bioelectron. 2016;86:202–10.

122. Lee JH, Kim JA, Kwon MH, Kang JY, Rhee WJ. In situ single step detection of exosome microRNA using molecular beacon. Biocatal. 2015;54:116–25.

123. Wu W, Yu X, Wu J, Wu T, Fan Y, Chen W, et al. Surface plasmon resonance imaging-based biosensor for multiplex and ultrasensitive detection of NSCLC-associated exosomal miRNAs using DNA programmed heterostructure of Au-on-Ag. Biosens Bioelectron. 2017;115:2835–44.

124. Liu C, Xu L, Li B, Situ B, Pan W, Hu Y, et al. Single-exosome-counting immunoassays for cancer diagnostics. Nano Lett. 2018;18:4226–32.

125. Wei P, Wu F, Kang B, Sun X, Heskea F, Pachot A, et al. Plasma extracellular vesicles detected by single molecule array technology as a liquid biopsy for colorectal cancer. J Extracellular Vesicles. 2020;9:1809765.

126. Wu W, Yu X, Wu J, Wu T, Fan Y, Chen W, et al. Surface plasmon resonance for biological and chemical sensing applications. ACS Nano. 2016;10:1802–9.

127. Lu J, Park JS, Huang C-H, Jo A, Cook K, Wang R, et al. An aptamer-based new method for competitive fluorescence detection of exosomes. Nanoscale. 2019;11:15589–95.

128. Zhou Y-G, Mohamadi RM, Poudineh M, Kermanshah L, Ahmed S, Safaei TS, et al. Interrogating circulating microsomes and exosomes using metal nanoparticles. Small (Weinheim an der Bergstrasse, Germany). 2016;12:727–32.

129. Jeong S, Park J, Pathania D, Castro CM, Weissleder R, Lee H. Integrated magneto-electrochemical sensor for exosome analysis. ACS Nano. 2016;10:1802–9.

130. Park J, Park JS, Huang C-H, Jo A, Cook K, Wang R, et al. An integrated magneto-electrochemical device for the rapid profiling of tumor extracellular vesicles from blood plasma. Nat Biomed Eng. 2021;5:678–89.

131. Homola J. Surface plasmon resonance sensors for detection of chemical and biological species. Chem Rev. 2008;108:462–93.

132. Zeng S, Bailleulage D, Ho H-P, Yong K-T. Nanomaterials enhanced surface plasmon resonance for biological and chemical sensing applications. Chem Soc Rev. 2014;43:3426–52.

133. Liu C, Zeng X, An Z, Yang Y, Eisenbaum M, Gu X, et al. Sensitive detection of exosomal proteins via a compact surface plasmon resonance biosensor for cancer diagnosis. ACS Sensors. 2018;3:1471–9.

134. Kneipp, Wang, Kneipp, Itzkan, Dasari, Feld. Population pumping of excited vibrational states by spontaneous surface-enhanced Raman scattering. Phys Rev Lett. 1996;76:2444–7.

135. Kwizera EA, O’Connor R, Vinduska V, Williams M, Butch ER, Snyder SE, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281–308.

136. Liu C, Zhao J, Tian F, Chang J, Zhang W, Sun J. A-DNA- and aptamer-mediated sorting and analysis of extracellular vesicles. J Am Chem Soc. 2019;141:3817–21.

137. Liu H, Yuen W, Pang Q, Xue C, Yan Z, et al. Liquid biopsy: noninvasive diagnosis and molecular phenotyping of breast cancer through microbead-assisted flow cytometry detection of tumor-derived extracellular vesicles (small methods 11/2018). Small Methods. 2018;2:1800050.

138. Liu H, Yuan W, Pang Q, Xue C, Yan Z. Single-particle analysis of tear fluid reveals abundant presence of tissue factor-exposing extracellular vesicles with strong coagulation activity. Talanta. 2021;239:123089.

139. Tan S, Xia L, Yi P, Han Y, Tang L, Pan Q, et al. Exosomal miRNAs in tumor microenvironment. J Exp Clin Cancer Res. 2020;39:67.

140. Wang Y, Liu J, Ma J, Sun T, Zhou Q, Wang W, et al. Exosomal circRNAs: biogenesis, effect and application in human diseases. Mol Cancer. 2019;18:116.

141. Ghandehar H, Sui X, Wood J, Nocera AL, Alli SC, Milane L, et al. Technologies and standardization in research on extracellular vesicles. Trends Biotechnol. 2020;38:1066–98.

142. Mateescu K, Kowal EJK, van Balkom BWM, Bartel S, Bhattacharyya SN, Buszó E, et al. Obstacles and opportunities in the functional analysis of extracellular vesicle BNA – an iSEV position paper. J Extracellular Vesicles. 2017;6:1286095.

143. Jaluira P, Konstantopoulos K, Betenbaugh M, Shiao J. A perspective on microarrays: current applications, pitfalls, and potential uses. Microb Cell Factories. 2007;6:4.

144. Bonachek K, Masud MK, Palma C, Phan H-P, Yamauchi Y, Hessain M, et al. Avoiding pre-isolation step in exosome analysis: direct isolation and sensitive detection of exosomes using gold-loaded nanoporous ferric oxide nanozymes. Anal Chem. 2019;91:3827–34.

145. Zhang P, Zhou X, Zeng Y. Multiplexed immunophenotyping of circulating exosomes on nano-engineered ExoProfile chip towards early diagnosis of cancer. Chem Sci. 2019;10:5495–504.

146. Tayebi M, Zhou Y, Tripathi P, Chandramohanadas R, Ai Y. Exosome purification and analysis using a facile microfluidic hydrodynamic trapping device. Anal Chem. 2020;92:10733–42.

147. Cho S, Yang HC, Rhee WJ. Simultaneous multiplexed detection of exosomal microRNAs and surface proteins for prostate cancer diagnosis. Biosens Bioelectron. 2019;146:111749.

148. Zhang Z, Tang C, Zhao L, Xu L, Zhou W, Dong Z, et al. Aptamer-based fluorescence polarization assay for separation-free exosome quantification. Nanoscale. 2019;11:10106–13.

149. Tayebi M, Tavakkoli Yaraki M, Yang HY, Ai Y. A MoS2–MWNT based fluorometric nanosensor for exosome detection and quantification. Nanoscale Adv. 2019;1:2866–72.

150. Wang S, Zhang L, Wan S, Canisz S, Cui C, Liu Y, et al. Aptasensor with expanded nucleotide using DNA nanotetrahedra for electrochemical detection of cancerous exosomes. ACS Nano. 2017;11:3943–9.

151. Dong H, Chen H, Jiang J, Zhang H, Cai C, Shen Q. Highly sensitive electrochemical detection of tumor exosomes based on aptamer recognition-induced multi-DNA release and cyclic enzymatic amplification. Anal Chem. 2018;90:4507–13.

152. Huang R, He L, Xia Y, Xu H, Liu C, Xie H, et al. A sensitive Aptasensor based on a hemin/G-Quadruplex-assisted signal amplification strategy for electrochemical detection of gastric cancer exosomes. Small (Weinheim an der Bergstrasse, Germany). 2019;15:e1900735.

153. Zhu L, Wang K, Cui J, Liu H, Bu X, Ma H, et al. Label-free quantitative detection of tumor-derived exosomes through surface plasmon resonance imaging. Anal Chem. 2014;86:8857–64.

154. Wang Q, Zou L, Yang X, Liu X, Nie W, Zheng Y, et al. Direct quantification of cancerous exosomes via surface plasmon resonance with dual gold nanoparticle-assisted signal amplification. Biosens Bioelectron. 2019;135:129–36.

155. Fan Y, Duan X, Zhao M, Wei X, Wu J, Chen W, et al. High-sensitive and multiplex biosensing assay of NSCLC-derived exosomes via different recognition sites based on SPRy array. Biosens Bioelectron. 2020;154:112066.

156. Sina AAI, Vaidyanathan R, Wuetherich A, Carrascosa LG, Trau M. Label-free detection of exosomes using a surface plasmon resonance biosensor. Anal Bioanal Chem. 2019;411:1311–8.

157. Thakur A, Xu C, Li WK, Qiu G, He B, Ng S-P, et al. In vivo liquid biopsy for glioblastoma malignancy by the AFM and LSPR based sensing of circulating exosomal CD44 and CD133 in a mouse model. Biosens Bioelectron. 2019;111:13476–8.

158. Shin H, Oh S, Hong S, Kang M, Kang D, Ji Y-G, et al. Early-stage lung cancer diagnosis by deep learning-based spectroscopic analysis of circulating exosomes. ACS Nano. 2020;14:5435–44.

159. Wang C, Ding Q, Plant P, Basheer M, Yang C, Tawedrous E, et al. Droplet digital PCR improves urinary using a facile microfluidic mRNA detection compared to real-time PCR. Clin Biochem. 2019;67:54–9.

160. Chen WW, Balaj L, Liau LM, Samuelis ML, Kotopoulous SK, Maguire CA, et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in...
glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic Acids. 2013;2:e109.

165. Zhang P, Zhou X, He M, Shang Y, Tettlow AL, Godwin AK, et al. Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip. Nat Biomed Eng. 2019;3:438–51.

166. Bai Y, Qu Y, Wu Z, Ren Y, Cheng Z, Lu Y, et al. Absolute quantification and analysis of extracellular vesicle IncRNAs from the peripheral blood of patients with lung cancer based on multi-colour fluorescence chip-based digital PCR. Biosens Bioelectron. 2019;142:111523.

167. Stella M, Falzone L, Caponnetto A, Gattuso G, Barbagallo C, Battaglia R, et al. Serum extracellular vesicle-derived circHIPK3 and circSMARCA2 are two novel diagnostic biomarkers for glioblastoma multiforme. Pharmaceuticals (Basel, Switzerland). 2021;14(7):618.

168. Lee J, Kwon MH, Kim JA, Rhe WJ. Detection of exosome miRNAs using molecular beacons for diagnosing prostate cancer. Artif Cells Nanomed Biotechnol. 2018;46:552–63.

169. Chen Y, Zhai L-Y, Zhang L-M, Ma X-S, Liu Z, Li N-M, et al. Breast cancer plasma biopsy by in situ determination of exosomal microRNA-1246 with a molecular beacon. Analyst. 2016;141:2264–76.

170. Oliveira GP, Zigon E, Rogers G, Davodian D, Lu S, Jovanovic-Talisman T, et al. Detection of extracellular vesicle RNA using molecular beacons. iScience. 2020;20:100782.

171. Chen X, Jia M, Liu L, Qiu X, Zhang H, Yu X, et al. High-fidelity determination and tracing of small extracellular vesicle cargoes. Small (Weinheim an der Bergstrasse, Germany). 2020;16:e2002800.

172. Zhang Y, Zhang X, Situ B, Wu Y, Luo S, Zheng L, et al. Rapid electrochemical biosensor for sensitive profiling of exosomal microRNA based on multifunctional DNA tetrahedron assisted catalytic hairpin assembly. Biosens Bioelectron. 2021;183:113205.

173. Yoshi GK, Deitz-McElvea S, Lyanage T, Lawrence K, Mall S, Sardar R, et al. Label-free Nanoplasmonic-based short noncoding RNA sensing at Attomolar concentrations allows for quantitative and highly specific assay of MicroRNA-10b in biological fluids and circulating exosomes. ACS Nano. 2015;9:11075–89.

174. Thakur A, Qiu G, Ng S-P, Liyanage T, Lawrence K, Mali S, Sardar R, et al. Direct detection of circulating exosomal miR-15b-3p enhances tumorigenesis and malignant transformation through the DYNLT1/Caspase-3/Caspase-9 signaling pathway in gastric cancer. J Exp Clin Cancer Res. 2020;39:32.

175. Cao L-Q, Yang X-W, Chen C, Zhang D-W, Jiang X-F, Xue P. Correction: Exosomal miR-21 regulates the TETs/PTENp1/PTEN pathway to promote hepatocellular carcinoma growth. Mol Cancer. 2020;19:59.

176. Nakano T, Chen IH, Wang C-C, Chen P-J, Tseng H-P, Huang K-T, et al. Circulating exosomal miR-92b: its role for cancer immunoeediting and clinical value for prediction of posttransplant hepatocellular carcinoma recurrence. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2019;19:3250–62.

177. Pang Y, Wang C, Lu L, Wang C, Sun Z, Xiao R. Dual-SENS biosensor for one-step detection of microRNAs in exosome and residual plasma of blood samples for diagnosing pancreatic cancer. Biosens Bioelectron. 2019;130:204–13.

178. Ko J, Bhagwat N, Yee SS, Ortiz N, Mahmoud A, Black T, et al. Combining machine learning and nanofluidic technology to diagnose pancreatic cancer using exosomes. ACS Nano. 2017;11:11182–93.

179. Lewis JM, Vyas AD, Qiu Y, Messer KS, White R, Heller MJ. Integrated analysis of exosomal protein biomarkers on alternating current electrokinetic chips enables rapid detection of pancreatic cancer in patient blood. ACS Nano. 2018;12:3311–20.

180. Carmichael J, Hayashi C, Huang X, Liu L, Lu Y, Krasnoslobodtsev A, et al. Label-free characterization of exosome via surface enhanced Raman spectroscopy for the early detection of pancreatic cancer. Nanomedicine. 2019;16:688–96.

181. Li-T-D, Zhang R, Chen H, Huang Z-P, Pe Y, Wang H, et al. An ultra-sensitive polyodopamine bi-functionalized SERS immunoassay for exosome-based diagnosis and classification of pancreatic cancer. Chem Sci. 2019;8:5372–82.

182. Pan B, Qin J, Liu X, He B, Wang X, Pan Y, et al. Identification of serum exosomal hsa-circ-0004771 as a novel diagnostic biomarker of colorectal cancer. Front Genet. 2019;10:1096.

183. Ma D, Huang C, Zheng J, Tang J, Li J, Yang J, et al. Quantitative detection of exosomal microRNA extracted from human blood based on surface-enhanced Raman scattering. Biosens Bioelectron. 2018;101:167–73.

184. Li Y, Deng J, Han Z, Liu C, Tan F, Xu R, et al. Molecular identification of tumor-derived extracellular vesicles using thermophoresis-mediated DNA computation. J Am Chem Soc. 2021;143:1290–5.

185. Lu F, Pan S, Qi Y, Li X, Wang J. The clinical application value of RDW, CA153, and HPV in breast cancer. Clin Lab. 2021;67(2).

186. Lee JU, Kim WH, Lee HS, Park KH, Sim SJ. Quantitative and specific detection of exosomal miRNAs for accurate diagnosis of breast cancer using a surface-enhanced Raman scattering sensor based on plasmonic head-flocked gold nanoparticles. Small (Weinheim an der Bergstrasse, Germany). 2019;15:e1804966.

187. Rodríguez M, Bajo-Santos C, Hessvik NP, Lorenz S, Fromm B, Berge V, et al. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol Cancer. 2017;16:156.
206. Zhou C, Chen Y, He X, Zheng Z, Xue D. Functional implication of exosomal miR-217 and miR-23b-3p in the progression of prostate cancer. Onco Targets Ther. 2020;13:11595–606.

207. Li S, Zhao Y, Chen W, Yin L, Zhu J, Zhang H, et al. Exosomal ephrinA2 derived from serum as a potential biomarker for prostate cancer. J Cancer. 2018;9:2659–65.

208. Zhu S, Ni Y, Sun G, Wang Z, Chen J, Zhang X, et al. Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: association with patient outcome under abiraterone. Cancer Med. 2021;10(18):6282–90.

209. Liu J, Yao J, Ho JY, Jung Y, Lee S, Hur SY, et al. Plasma-derived exosomal miR-4732-5p is a promising noninvasive diagnostic biomarker for epithelial ovarian cancer. J Ovarian Res. 2021;14:59.

210. Zhu Y, Wang S, Xi X, Zhang M, Liu X, Tang W, et al. Integrative analysis of long extracellular RNAs reveals a detection panel of noncoding RNAs for liver cancer. Theranostics. 2021;11:181–93.

211. Preis M, Gardner TB, Gordon SR, Pipas JM, Mackenzie TA, Klein EE, et al. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2011;17:5812–21.

212. Han L, Shi W-J, Xie Y-B, Zhang Z-G. Diagnostic value of four serum exosome microRNAs panel for the detection of colorectal cancer. World J Gastrointest Oncol. 2021;13:970–9.

213. Aidoo-Brown J, Moschou O, Estrela P. Multiplexed prostate cancer companion diagnostic devices. Sensors (Basel, Switzerland). 2021;21(15):5023.

214. McKiernan J, Donovan MJ, O’Neill V, Bentink S, Noerholm M, Belzer S, et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2016;2:682–8.

215. McKiernan J, Donovan MJ, Margolis E, Partin A, Carter B, Brown G, et al. A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2-10ng/ml at initial biopsy. Eur Urol. 2018;74:731–8.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.